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SPECIFIC AIMS 144 
Multiple sclerosis (MS) is a progressive neurological disease of the central nervous system (CNS) 145 
affecting an estimated 2.5 million people worldwide.  Marked by lesions in the brain and spinal cord, MS 146 
leads to conduction abnormalities that manifest in numerous physiological symptoms.  Of great concern, 147 
~60% of individuals with MS experience temporary symptom worsening upon elevations in body 148 
temperature, a process known as Uhthoff’s phenomenon.  Adding further complexity, subjective 149 
observations suggest these individuals have an altered ability to sweat upon exposure to heat, while skin 150 
blood flow responses remain unexamined.  Consequently, these individuals could face a vicious cycle of 151 
heat sensitivity (i.e., Uhthoff’s phenomenon) and an inability to control body temperature due to blunted 152 
thermoregulatory responses.  As such, the MS pathophysiology creates a unique obstacle, further 153 
impeding quality of life for those suffering from the disease.  With this in mind, the goal of this 154 
dissertationl is to understand how MS impacts the control and function of the thermoregulatory system 155 
(i.e., sweat output & skin blood flow).  Therefore, the first objective of the dissertation is to test the 156 
hypothesis that MS blunts the control of thermoregulatory end organ responses to increases in body (i.e., 157 
“core”) temperature.  To accomplish this objective, the following specific aims will be tested: 158 
 Specific Aim 1: To determine if MS effects the autonomic control of the thermoregulatory effector 159 
organs during passive whole-body heating.  Sweating and skin blood flow will be assessed in MS and 160 
control subjects during normothermic and hyperthermic (i.e., heating the body externally) conditions.  161 
Core temperature (Tcore) will be manipulated via tube-lined water perfusion suits.  Thermoregulatory 162 
responses, recorded from an uncovered forearm, will be a result of increased temperature sensed and 163 
processed centrally rather than any local influence of the suit.  Findings from Specific Aim 1 will provide 164 
evidence of dampened control of the thermoregulatory system in MS, with insight as to where the 165 
dysfunction primarily occurs (sweat glands vs skin blood vessels).  The subsequent question of how this 166 
dysfunction translates to a real-life situation will need answering. 167 
As the perfusion suit covers ~85% of subject’s body in Specific Aim 1, participant’s 168 
thermoregulatory system is operating in an encapsulated micro-environment. In a real-world setting such 169 
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as physical activity the body is free from encapsulation, thus more readily capable of exchanging heat 170 
with the external environment.  In this scenario, heat is produced from exercising muscle that must be 171 
either: 1) stored, thus elevating Tcore; or 2) met with appropriate heat loss responses (e.g., sweat and skin 172 
blood flow) to mitigate the rise in body temperature.  If MS suppresses the thermoregulatory system, 173 
exercise could elicit exaggerated increases in Tcore relative to healthy individuals.  Thus, the second 174 
objective of the dissertation is to test the hypothesis that MS blunts thermoregulatory responses to 175 
exercise compared to healthy controls, thus leading to exaggerated increases in Tcore.  To accomplish this 176 
objective, the following specific aim will be investigated: 177 
 Specific Aim 2: To determine if MS effects thermoregulatory responses to exercise of a fixed heat 178 
production.  This objective will be accomplished by comparing thermoregulatory responses (Tcore, skin 179 
blood flow, sweat rate, sweat gland recruitment & sweat loss) to exercise of a fixed metabolic (i.e., 180 
internal) heat production in healthy controls and individuals with MS.  181 
 The findings of reduced thermoregulatory function in MS from Specific Aims 1 and 2 will likely 182 
be central in origin due to the nature of the disease, however peripheral maladaptations cannot be ruled-183 
out.  Therefore, the third objective of the dissertation is to test the hypothesis that individuals with MS 184 
have similar sweating and skin blood flow responses to a peripherally-administered thermoregulatory-185 
organ agonist relative to healthy controls, independent of changes in Tcore. To accomplish this objective, 186 
the following specific aim will be tested: 187 
 Specific Aim 3: To determine if MS effects sweat gland and cutaneous vasculature responses to 188 
peripheral stimuli independent of changes in core temperature.  This objective will be accomplished by 189 
comparing sweat gland and skin blood flow responses to infusions of thermoregulatory end-organ 190 
agonists (methacholine & sodium nitroprusside) through microdialysis probes placed in the skin.  Using 191 
this technique allows the investigation of peripheral impairment, as measured responses are independent 192 
of any changes in Tcore.  Specifically, methacholine will be used to test sweat output and vasodilation of 193 
the skin vessels via adequate endothelial cell function (endothelial dependent). Cutaneous vasodilatory 194 
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responses to sodium nitroprusside (nitric oxide donor) occurs independent of endothelial cells (endothelial 195 
independent). 196 
The projects laid out in this dissertation are essential to understanding how MS impacts the 197 
thermoregulatory system.  Using these established techniques, our results will arm clinicians with 198 
mechanistic insight of the effects of MS on this system, and potentially alter the current treatment 199 
strategies physicians adhere to.  In addition, the results of this study may be used to develop novel cooling 200 
strategies or treatments that could substantially improve the quality of life for individuals living with MS, 201 
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ABSTRACT 237 
Multiple sclerosis (MS) is an autoimmune disease known for the demyelination that occurs in the 238 
central nervous system (CNS).  While disruptions in neural conduction in the CNS is a hallmark 239 
of MS, evidence indicates that this demyelination can also lead to autonomic dysfunction in the 240 
peripheral nervous system.  Individuals with MS experience a wide range of symptoms as a 241 
result of neural signal disruption, and these symptoms are prone to a temporary severe worsening 242 
when individuals with MS are hyperthermic (known as Uhthoff’s phenomenon).  Because of the 243 
prevalence and dangers associated with Uhthoff’s phenomenon, investigators have made it a 244 
priority to assess the ability of those with MS to ward off this occurrence by investigating the 245 
mechanisms by which humans dissipate of heat.  The findings of several studies clearly indicate 246 
that MS reduces the ability for an individual to secrete sweat on the skins surface, however the 247 
impact of this reduction in heat loss capacity remains somewhat unclear.  Additionally, it appears 248 
blood flow to skin is preserved during hyperthermia, and likely doesn’t significantly contribute 249 
to the thermoregulatory deficits frequently observed in this population.  In effort to supplement 250 
dampened thermoregulatory control, several cooling strategies have been assessed in MS, with 251 
most evidence indicating pharmaceutical interventions, precooling, and/or cold fluid ingestion 252 
are most impactful.  More research should focus on the impact of blunted sweating responses in 253 
MS on the ability of these individuals to control body temperature, and thus potentially reduce 254 
the frequency at which Uhthoff’s phenomenon occurs.  255 
 256 
  257 
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MULTIPLE SCLEROSIS 258 
Multiple sclerosis (MS) is an autoimmune disease affecting ~2.5 million people 259 
worldwide. Although the direct cause has yet to be established, the pathophysiology is marked 260 
by unknown antigens activating T-lymphocytes, B-lymphocytes, and other immune responders 261 
crossing the blood-brain barrier and attacking myelin surrounding neurons within the central 262 
nervous system (CNS).  Specifically, these activated immune cells identify myelin as a foreign 263 
invader and release phagocytic cytokines labeling it for destruction.  Demyelination and 264 
ultimately axonal damage, dramatically disrupting neural conduction within the CNS.  As axonal 265 
exposure increases due to myelin loss, there are corresponding changes to axonal physiology 266 
including a loss of saltatory properties of electrical conduction, reduction in conduction velocity, 267 
and a predisposition to conduction block (28).  This pathology leads to a complex array of 268 
symptoms reported in persons with MS that is largely dependent on the location of myelin 269 
damage (i.e., lesions) as well as density of these lesions in a given area of the CNS (Table 1). 270 
 Accumulating evidence suggests MS leads to dysfunction in the autonomic nervous 271 
system (8, 19, 48) and impaired control of genito-urinary, gastrointestinal, and cardiovascular 272 
systems.  This manifests itself in the form of bladder dysfunction (4, 29), sexual dysfunction (55) 273 
and cardiovascular abnormalities including: responses to hypotensive challenges (2, 18, 35), 274 
responses to sympatho-excitatory maneuvers (35), and reduced sympathetic nerve activity (21).  275 
Assessing and understanding autonomic dysfunction in MS can be challenging due to variability 276 
in early clinical symptomology and heterogeneity in the clinical course over time (Figure 1).  In 277 
addition, mechanisms responsible for autonomic dysfunction due to MS can be difficult to isolate 278 
and interpret as it may involve sensory impairments, altered neural integration within the CNS, 279 
impaired effector responses, or combinations of all of these factors.  Of particular interest to this 280 
 13 
journal, the accumulation of past and recent work suggests the autonomic control of 281 
thermoregulatory function is also compromised in individuals with MS (1, 36, 46, 47, 55).  282 
Given the brevity and specificity of this review, the abnormalities and thermoregulatory 283 
dysfunction associated with hyperthermia will be the focus of this paper.  Additionally, 284 
information regarding current treatment strategies, cooling strategies, and direction of future 285 
research will also be outlined. 286 
 287 
MULTIPLE SCLEROSIS AND HEAT 288 
Uhthoff’s Phenomenon 289 
Complicating MS symptomology, 53-95% of these individuals suffer from severe heat 290 
intolerance, known as Uhthoff’s phenomenon (15, 16, 34).  Upon modest increases in body 291 
temperature of~0.3 ºC or less (12, 16, 34, 42), there is a temporary but severe worsening of MS 292 
symptomology that subsides once temperature returns toward normothermia.  This occurrence 293 
was documented and ultimately named after German ophthalmologist Wilhelm Uhthoff, in 294 
which patients immersed in a warm bath reported temporary worsening of their vision (53).  As 295 
such, the warm bath test was an early diagnostic technique for MS prior to advances in medicine.  296 
While more advanced and comprehensive diagnostic techniques have been adopted, Uhthoff’s 297 
phenomenon has continued to puzzle clinicians and researchers alike. 298 
While the conduction of action potentials occurs along demyelinated segments of axons, 299 
propagation is slower and with less fidelity compared to myelinated axons.  Over time, it is 300 
thought there is an increase in Na+ channel expression on the exposed axon transforming 301 
conduction from nodal/paranodal-mediated saltatory conduction (fast and high-fidelity) to serial 302 
membrane transmission (slow and low-fidelity) across demyelinated areas of the axon (26–28, 303 
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31).  As the reduction in myelin leaves more of the axon exposed, more current is also likely to 304 
escape from the axon thus slowing neural conduction in individuals with MS.  This increases the 305 
likelihood that K+ escapes, thus reducing the proportion of voltage available relative to the 306 
voltage required needed to excite a node of Ranvier (i.e., axonal safety factor).  Reductions in 307 
safety factor leaves the subsequent node of Ranvier unable to register the voltage necessary for 308 
the highly concentrated voltage-gated Na+ channels to generate action potential propagation, thus 309 
eventually leading to conduction failure.  Additionally, it is thought that these newly expressed 310 
Na+ channels are temperature-sensitive, and thus remain closed when temperatures are elevated.  311 
It is this Na+ channel temperature sensitivity that may be responsible for eliciting the temporary 312 
increase in symptomology frequently observed (12, 16, 52) during hyperthermia.  However, this 313 
notion has not been directly tested on MS neurons in vivo, thus more research is warranted to 314 
uncover the exact cause of Uhthoff’s phenomenon among individuals with MS. 315 
Given the complexity of MS and the interplay between increases in body temperature and 316 
the development of Uhthoff’s phenomenon, it is imperative to understand the capability of 317 
individuals with MS to rid the body of heat.  If the primary impetus for Uhthoff’s phenomenon is 318 
deviations in body temperature and these individuals face a diminished ability to activate heat 319 
dissipation mechanisms, this could render individuals with MS supremely vulnerable to an 320 
unwanted and often dangerous aspect of their disease. 321 
 322 
EFFERENT THERMOREGULATORY RESPONSES 323 
 Humans rely on the autonomic nervous system to maintain body temperature within a 324 
narrow range.  Upon exposure to a rising core temperature, thermoreceptors at the skin and the 325 
core provide afferent information that is relayed to the preoptic area of the hypothalamus (6, 33, 326 
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43, 50). This brain center modulates heat dissipation via proportional increase in autonomic 327 
signaling to thermoregulatory effector organs (i.e. sweat glands and cutaneous vasculature) in an 328 
effort to dissipate heat from the body to the environment.  If done adequately under compensable 329 
conditions, increases in core temperature will be mitigated to a thermal steady-state until the heat 330 
stress (environmental, exercise, or both) has subsided.  The control of skin blood flow and 331 
sweating may be more crucial in MS (56) as small increases in core temperature can elicit 332 
worsening of clinical signs and symptoms through Uhthoff’s phenomenon.  Given MS primarily 333 
disrupts autonomic signaling in the CNS, it not surprising that conduction abnormalities caused 334 
by MS impact autonomic thermoregulatory reflex (1, 36, 46, 55). 335 
Sweat Function in MS 336 
Under hyperthermic conditions, humans primarily rely on the evaporation of sweat to 337 
cool the skin’s surface.  The neural integration of perspiration originates in the preoptic area of 338 
the hypothalamus (3, 30, 50), travels through the medullary raphe region of the brainstem before 339 
activating the intermediolateral nucleus of the spinal cord (50, 51) and exiting the CNS to the 340 
periphery.  Once in the periphery, the neural signal travels down sympathetic post-ganglionic 341 
cholinergic axons (54) to ultimately activate eccrine sweat glands via acetylcholine binding to 342 
M3 muscarinic receptors (37).  With this neural reflex in mind, Noronha et al. (36) investigated 343 
sweat function in individuals with MS utilizing a heat cradle increase body temperature to 344 
observed changes in coloration due to sweating of iodine-stained powder placed on the skin.  345 
This study provided observational evidence of reduced sweating responses (48% of individuals 346 
with MS had visible sweating abnormalities), however this technique did not allow for 347 
quantification of the magnitude or impact of sudomotor dysfunction.  Despite this limitation, this 348 
“thermoregulatory sweat test” provided crucial evidence that MS impacts autonomic control of 349 
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the thermoregulatory system (8, 55).  Davis et al. (13) utilized intradermal iontophoresis to 350 
quantify sweat output in MS.  This technique delivers a supramaximal concentration of 351 
pilocarpine (cholinergic agonist) to elicit maximal eccrine sweat gland activation and output 352 
independent of the CNS.  Diminished sweat function was identified in individuals with MS, and 353 
this reduction was not caused by a reduction in the number of sweat glands recruited, but rather 354 
reduced sweat gland output per gland.  Additional findings found no improvements in sweat 355 
output in individuals with MS patients following aerobic exercise training suggesting 356 
impairments were not due to decreased physical activity and thus detraining often seen in this 357 
clinical population.  These findings were critical as they were the first to identify end-organ 358 
impairment independent of central mechanisms.  However, understanding maximal sweat 359 
outputs provides limited information on how the thermoregulatory system operates as a negative-360 
feedback control system to regulate the thermal status of an individual.  In an attempt to examine 361 
thermoregulatory function, Saari et al. assessed sweating during 15 min of passive heating the 362 
upper torso.  Differences in transepidermal water loss were observed in the lower limbs of 363 
individuals with MS , indicating likely reductions in sweat rate (46).  Using more robust passive 364 
whole-body heating, thermoregulatory reflex control of sweating responses was assessed by 365 
placing individuals with MS in a tube-lined suit covering ~85% of the body’s surface area 366 
through which 48-50 °C water was perfused to increase skin temperature, leading to an increase 367 
in core temperature (~0.8 °C).  The suit covers the entire body surface area except the head, 368 
hands, feet, and regions of sweating and skin blood flow assessment on the dorsal forearm.  369 
Measurements of sweat rate (capacitance hygrometry) recorded from an exposed limb during this 370 
passive heat stress are thought to be representative of reflex-induced neural modulation in 371 
response to changing internal body temperature (i.e., adequate sensing of increased internal body 372 
 17 
temperature leading to proportional activation of efferent thermoregulatory end organs), as direct 373 
local heating from the suit does not influence the unexposed measurement site.  Using this 374 
approach, investigators can control heat gained by subjects via water-perfusion suits, thus 375 
examining increases in sweat rate as a “dose-response” function of increases in core temperature. 376 
This directly tests the sensitivity of the thermoregulatory reflex initiated in the CNS.  Blunted 377 
reflex control of sweating in MS was apparent at relatively moderate increases in core 378 
temperature (~0.8 °C), likely due to impairments in neural control of sudomotor pathways or 379 
neural-induced changes in eccrine sweat glands. 380 
Combining the aforementioned studies, there is definitive evidence of sweating 381 
abnormalities in response to increases in body temperature in MS.  What has remained unknown 382 
is how these observed sweating abnormalities translate to thermoregulatory function encountered 383 
in a more practical setting (i.e., physical activity).  This question has recently been addressed by 384 
Allen et al. (in review) measuring thermoregulatory function during exercise intensity of a fixed 385 
metabolic heat production in both individuals with MS and matched healthy counterparts.  In this 386 
study, individuals with MS had significantly suppressed whole-body sweat loss compared to 387 
healthy controls, as well as a significantly reduced thermosensitivity (i.e., the slope of the 388 
relationship between mean body temperature and sweat rate).  However, measures of local sweat 389 
rate, core temperature, sweating onset time, and sweating onset threshold were all similar 390 
between groups.  Taken together, the results of this study indicate that there are differences in 391 
total sweat secretion, as well as the sensitivity to the neural drive for sweat secretion, but the 392 
impact of these differences may not be apparent during exercise of relatively modest heat loads 393 
in temperate environments.  Clearly the understanding of the impact of thermoregulatory 394 
abnormalities as a result of MS are far from complete.  Future studies should investigate the 395 
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capacity of the thermoregulatory system in individuals with MS under more strenuous 396 
conditions. 397 
The culmination of studies on MS and sweating demonstrate a significantly suppressed 398 
thermoregulatory sweating response to heat generated either passively or actively.  Under the 399 
right conditions, this dysfunction could lead to elevated core temperature responses to exercise, 400 
however the magnitude of the impact of these abnormalities remains unclear.  Given the 401 
prevalence of Uhthoff’s phenomenon in the MS population future studies are urgently needed on 402 
this as increases in core temperature is a critical, sometimes dangerous, aspect of this disease.  403 
Cutaneous Vascular Function 404 
In response to elevations in body temperature, cutaneous blood vessels dilate via a 405 
combination of both passive and active vasodilation.  In some cases, blood flow shunted to the 406 
skin vasculature can reach nearly 8 L/min (44, 45) in heat stressed humans.  This blood warms 407 
the skin’s surface, thus creating a thermal gradient between the skin and ambient air that elicits 408 
radiative heat loss from the body to the environment (provided the ambient environment is 409 
temperate), while also delivering fluid to the secretary coil of sweat glands for perspiration.  410 
Active cutaneous vasodilation requires the neural activation of sympathetic cholinergic neurons 411 
to stimulate endothelial cells to release vasoactive agents (nitric oxide, prostaglandins, 412 
vasoactive intestinal peptide, etc.), causing smooth muscle relaxation and ultimately vasodilation 413 
(20, 22, 23).  As such, MS could potentially have a detrimental impact on the neural control of 414 
skin blood flow. 415 
Two recent studies have investigated the control of skin blood flow in response to heat 416 
exposure in MS.  In the aforementioned study by Allen et al. (1), no differences in cutaneous 417 
vascular conductance (CVC, an index of skin blood) were observed between individuals with 418 
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MS and healthy controls as a result of increasing core temperature 0.8 °C during passive whole-419 
body heating.  Additionally, maximal cutaneous vascular responses to a locally heating of the 420 
skin (42 °C) for 30 min were similar between person with MS and healthy matched controls.  421 
These findings were further supported in a subsequent study by the same group in which 422 
cutaneous vascular responses were assessed during physical activity (Allen et al., in review).  423 
Together these studies suggest the control of the skin vasculature remains intact in MS, however 424 
additional studies targeting cutaneous vascular control/function are clearly warranted. 425 
 426 
THERMOSENSORY FUNCTION 427 
 While there is a clear need for understanding efferent thermoeffector organ responses to 428 
heat stress in MS, it is also imperative to study afferent sensory function to assess the complete 429 
picture of the involvement of MS in the thermoregulatory reflex arc.  The ability to sense changes 430 
in skin temperature represents a key trigger for behavioral responses to heat stress (e.g., reducing 431 
physical work, removing clothing, seeking shade) and could affect autonomic thermoregulation 432 
as well.  Fundamental information regarding thermal sensitivity during a thermal stress would be 433 
equally valuable.  In a recent study, Filingere et al. investigated afferent thermosensitivity in MS 434 
during exercise (14).  Sensitivity to tightly controlled cold- and warm-stimuli was assessed at 435 
normothermic baseline and exercise-induced hyperthermia (~0.4 °C increase in core 436 
temperature).  Novel findings from this study demonstrated that individuals with MS have a 437 
reduced sensitivity to cold (transmitted by myelinated fibers) but not warm (transmitted by 438 
unmyelinated fibers) stimuli.  This breakthrough study was the first to indicate MS 439 
independently modulates afferent thermosensory function.  This study has opened new doors and 440 
perspectives on how the MS pathophysiology effects the afferent arm of the thermoregulatory 441 
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reflex, but clearly more emphasis on the effect of heat on afferent signaling, central processing 442 
and behavioral thermoregulatory responses in MS is warranted. 443 
 444 
THERAPEUTIC INTERVENTIONS 445 
 Given the consistent evidence for thermoregulatory dysfunction, there is an obvious need 446 
to provide avenues to mitigate this dysfunction and prevent excessive increases in body 447 
temperature.  Several possibilities exist; however, few have been experimentally tested.  Such 448 
possibilities include: pharmaceutical therapies, cooling prior to exercise (i.e., precooling), or 449 
cooling during physical activity.  Given the brevity of this priority review, a short description of 450 
current heat mitigation strategies will be provided.   451 
Pharmaceutical Therapies  452 
Little is known surrounding the effects of current MS pharmacological therapies on the 453 
thermoregulatory system.  In terms of avoiding the potentially dangerous effects of Uhthoff’s 454 
phenomenon, a promising symptom-modifying therapy, 4-aminopyridine, has demonstrated 455 
some beneficial effects on thermoregulatory function in preliminary work.  4-aminopyridine acts 456 
as a voltage-gated K+ channel blocker, often used to aid in neural conduction and often 457 
prescribed to improve common symptoms (e.g., gait difficulties, visual disturbances, etc.) in MS 458 
(5, 11, 24, 41).  In a small single-blinded double crossover study (n=11), 4-aminopyridine 459 
significantly reduced resting core temperature compared to placebo, as well as significantly 460 
reducing the temperature required before sweat onset (17).  This beneficial effect was thought to 461 
be protective against the excessive rise in core temperature (16), essentially acting as a buffer in 462 
which sweating can occur at a lower temperature threshold, while also providing a greater range 463 
of core temperatures before dangerous heat sensitivity is experienced.  While the use of 4-464 
 21 
aminopyridine has demonstrated promising results, larger-scale studies should be implemented 465 
to confirm these preliminary findings.  Additionally, more research should be focused on 466 
pharmacologically manipulating neural signal preservation during heat stress.  467 
Cooling Prior to Exercise 468 
 While pharmacological measures to mitigate heat-related MS problems remains a 469 
relatively unexplored territory, cooling individuals with MS prior to activity (i.e., precooling) 470 
could be a simple method by which Uhthoff’s phenomenon can be delayed or avoided.  In 471 
healthy individuals, precooling subjects in a cold ambient environment (i.e., sitting in a cold 472 
environmental chamber) prior to exercise elicits increased time to exhaustion (25), reduced 473 
steady state heart rate (38), and a reduction in core temperature required for the onset of sweating 474 
(49).  While this precooling strategy was very impactful for those with MS, it is improbable that 475 
this technique is widely implemented in practice.  With this in mind, White et al.(57) used a 476 
more practical method of precooling by immersing the lower body in cold water (~16 °C) for 30 477 
minutes prior to exercise.  This precooling method preserved 6-minute walk test performance 478 
following exercise, blunted increases in HR and RPE throughout exercise, as well as mitigated 479 
the rise in rectal temperature throughout the exercise bout.  It appears this simple and well-480 
tolerated lower limb cold-water immersion may be a practical and effective technique to prevent 481 
unwanted heat-related difficulties associated with MS.  482 
Cooling During Exercise 483 
 While precooling could be used as an effective means by which to mitigate rises in core 484 
temperature and increase exercise performance, cooling methods during exercise could also have 485 
thermal benefits for individuals with MS.  The use of commercially available heat vests, caps 486 
and neck pads have an advantageous impact on fatigue, function and physical performance in 487 
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healthy individuals (7, 39), however little is known regarding the efficacy of cooling individuals 488 
with MS during physical activity.  Similar to cooling vests, the use of artificial sweat may be 489 
another practical intervention to aid in the thermoregulatory process.  Although surprisingly 490 
understudied, spraying the skin’s surface with water could serve as additional sweat on the skin’s 491 
surface, thus potentially participating in heat exchange from the body to the environment.  As of 492 
the composition of this article, only one study has assessed this notion in a clinical population 493 
also prone to thermoregulatory deficits (40).  In this study, individuals with a spinal cord injury 494 
were encouraged to spray water on their skin ad libitum during an incremental exercise test.  495 
Although the results of this study indicated similar thermal responses to control (no artificial 496 
sweat) conditions, methodological constraints may have limited the investigators ability to detect 497 
differences between conditions.  The effectiveness of artificial sweat in individuals with MS 498 
warrants further investigation. 499 
 Cold fluid ingestion is a promising and practical approach to cooling that has been 500 
experimentally-tested on individuals with MS during exercise (9).  By taking the simple 501 
approach of providing cold (1.5 °C) water to subjects every 15 min of exercise in a hot 502 
environment (33 °C, 30% RH), individuals with MS were able to cycle ~30% longer than 503 
ingesting thermoneutral (37 °C) water in the same environmental conditions.  While the cooling 504 
effect on core temperature was minimal, clearly the use of cold water ingestion could provide a 505 
benefit to individuals with MS seeking to live a physically active lifestyle.  Additionally, the 506 
findings from this study raise additional questions of the impact of abdominal cold-sensitive 507 




 Heat presents a unique challenge to individuals with MS.  While MS-induced heat 511 
intolerance is a well-established occurrence known as Uhthoff’s phenomenon, compounding 512 
evidence suggests this population also experiences thermoregulatory deficits, especially in the 513 
autonomic control of sweating thus weakening their ability to combat the onset of Uhthoff’s 514 
phenomenon.  Although accumulating evidence demonstrates a reduction in sweating responses 515 
among individuals with MS, further research should focus on assessing the impact of these 516 
reductions on the regulation of body temperature during physical activity.  Additionally, while 517 
there may be means by which individuals with MS can supplement their thermoregulatory 518 
responses such as pharmacological intervention, precooling and other strategies, more attention 519 
should be focused on reducing the frequency of Uhthoff’s phenomenon.  Finally, future research 520 
should be directed toward understanding afferent thermosensory function and behavioral 521 
thermoregulation in MS, as these may have the greatest practical impact for individuals suffering 522 
from this disease. 523 
  524 
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Table 1.  Common symptoms of multiple sclerosis (National Multiple Sclerosis Society, 2018). 673 
 674 
Most Common Symptoms  Less Common Symptoms 
• Fatigue  • Speech Disorders 
• Walking (Gait), Balance, & 
Coordination Problems 
 • Swallowing Problems 
• Bowel Dysfunction  • Headache 
• Dizziness and Vertigo  • Hearing Loss 
• Pain  • Seizures 
• Emotional Changes  • Tremor 
• Spasticity  • Respiration / Breathing Problems 
• Numbness  • Itching 
• Bladder Dysfunction   
• Vision Problems   
• Sexual Dysfunction   
• Cognitive Function   
• Depression   
 675 
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Figure 1. 687 
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CHAPTER 2 690 
 691 
Does MS impair the autonomic control of sweat glands and the cutaneous vasculature 692 




Although impairments in sweating have been suggested previously, the techniques utilized to 697 
assess these differences are limited and often unable to quantify impairments, nor assess the 698 
magnitude of impairments.  Additionally, the control of the cutaneous vasculature as well as the 699 
thermoregulatory reflex has yet to be studied in MS.  The following study takes an approach that 700 
addresses these limitations and allows for comparisons between individuals with MS and healthy 701 
CON; potentially uncovering how MS impacts the thermoregulatory reflex control of sweat rate 702 
and skin blood flow. 703 
  704 
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ABSTRACT 737 
Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system (CNS), 738 
disrupting autonomic function.  The aim of this study was to test the hypothesis that individuals 739 
with MS have blunted control of thermoregulatory reflex increases in sweat rate (SR) and 740 
cutaneous vasodilation compared to controls during a passive whole-body heat stress (WBH).  741 
Eighteen individuals with relapsing-remitting MS and 18 healthy controls (CON) participated in 742 
the study.  Core temperature (Tcore), skin temperature, heart rate, arterial blood pressure (10 min 743 
intervals), skin blood flow (laser-Doppler flux: LDF), and SR were continuously measured 744 
during normothermic baseline (34 °C water perfusing a tube-lined suit) and WBH (increased 745 
Tcore 0.8 °C via 48 °C water perfusing the suit).  Following WBH, local heaters were warmed to 746 
42 °C, inducing peak cutaneous vasodilation at the site of LDF collection.  Cutaneous vascular 747 
conductance (CVC) was calculated as the ratio of LDF to mean arterial pressure and expressed 748 
as a percentage of peak achieved during local heating.  Individuals with MS had attenuated SR 749 
responses to WBH (∆ SR from baseline: CON: 0.65±0.27; MS: 0.42±0.17 mg/cm2/min, 750 
p=0.003), while ∆ %CVC42C from baseline was similar between groups (CON: 42±16%; MS: 751 
38±12 %, p=0.39).  SR responses were blunted as a function of Tcore in MS (interaction: 752 
group*Tcore, p=0.03), of which differences were evident at ∆ Tcore 0.7 °C and 0.8 °C (p<0.05).  753 
No interaction was observed in ∆ %CVC42C.  Taken together, MS blunts sweating responses, 754 
while control of the cutaneous vasculature is preserved in response to WBH. 755 
 756 
  757 
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NEW AND NOTEWORTHY 758 
 This study is the first to assess the reflex control of the thermoregulatory system in 759 
individuals living with MS.  The novel findings are twofold.  First, attenuated increases in sweat 760 
rate in MS compared to healthy controls were observed in response to a moderate increase (0.8 761 
°C) in core temperature via passive whole-body heat stress.  Second, it appears the reflex control 762 
of the cutaneous vasculature is preserved in MS. 763 
  764 
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INTRODUCTION 765 
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system 766 
(CNS).  As the most prominent neurological disorder in young adults, the National Multiple 767 
Sclerosis Society estimates that 400,000 individuals are currently living with MS in the United 768 
States, and 2.3 million worldwide (54).  The pathology of MS is marked by chronic autoimmune 769 
attacks via activated T cells, leading to the penetration of the blood-brain barrier that ultimately 770 
results in demyelination of axons within the CNS, replacing the healthy myelin with lesions (i.e., 771 
damaged myelin).  Through demyelination of axons within the CNS, there is a loss of conductive 772 
properties that increase the risk for reduced conduction velocity (16, 44), conduction strength 773 
and potentially conduction block (11, 46).  Loss of adequate neural conduction has been shown 774 
to cause a wide-range of MS-related symptomatology, including but not limited to:  visual 775 
dysfunction (19), gait ataxia (20, 26, 34), bladder dysfunction (4, 35), fatigue (5, 29, 36), as well 776 
as autonomic dysfunction (1, 23, 24, 27, 38, 41). 777 
While the effects of MS can widely vary among individuals, the majority (60-90%) of 778 
MS patients experience a profound heat intolerance known as Uhthoff’s phenomenon (15, 17–779 
19) which elicits a temporary worsening of disease-related symptomatology as a result of 780 
increased internal temperatures (e.g., warm environments and/or exercise).  In some cases, an 781 
increase as little as 0.5 ºC in core temperature (Tcore) is sufficient to elicit Uhthoff’s phenomenon 782 
(39).  Although dangers of heat intolerance (e.g., loss of vision, loss of motor control, extreme 783 
fatigue, etc.) in MS are well established (19, 22, 40, 52), little progress has been made in regards 784 
to understanding the effect of MS on the control of thermoregulatory reflex responses (i.e., skin 785 
blood flow and sweating) that are employed to prevent excessive increases in Tcore. 786 
 38 
Autonomic thermoregulatory responses to increases in Tcore require appropriate neural 787 
integration within the CNS.  Heretofore, little research has been focused on understanding the 788 
effect of MS on the reflex control of cutaneous vascular and sudomotor function.  Although 789 
primarily qualitative, sudomotor dysfunction in MS patients has been reported (7, 38, 41, 51).  790 
Using a gross qualitative investigative approach, during a thermoregulatory sweat test (quinzarin 791 
powder), investigators have observed alterations or impairments in sweating as a result of MS (7, 792 
38, 51).  Using a more direct approach, Davis et al. demonstrated that individuals with MS had a 793 
significantly reduced sweat rate and sweat output per gland despite similar total sweat gland 794 
recruitment relative to healthy controls when maximal sweat responses from a small area of the 795 
dorsal forearm were evoked using iontophoresis of an acetylcholine agonist (pilocarpine) (14).  796 
These data are noteworthy as they identify evidence of end-organ impairments, despite MS being 797 
primarily a CNS disease, but only provide inferences regarding the maximal capacity rather than 798 
a sweat rate (SR) obtained during a patient-relevant heat stress.  Additionally, the other primary 799 
thermoregulatory mechanism of heat dissipation, skin blood flow, has not been assessed in 800 
individuals with MS. 801 
 Using a water perfusion suit to induce a whole-body heat stress (WBH) provides a 802 
reliable technique to investigate thermoregulatory reflex control of the cutaneous vasculature and 803 
sweat glands.  By covering ~85% of the body’s surface area with a suit perfusing warm water, 804 
investigators can use the suit as a tool to heat the body, ultimately leading to a significant 805 
increase in Tcore.  Subsequent measurements recorded from an exposed limb (e.g., an uncovered 806 
forearm) are thought to be representative of the thermoregulatory reflex (i.e., adequate sensing of 807 
increased Tcore, leading to proportional activation of efferent thermoregulatory end organs), as 808 
direct local heating from the suit does not influence the unexposed measurement site.  Therefore, 809 
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the use of this technique in assessing the neural control of efferent thermoregulatory responses 810 
could provide valuable insight into MS involvement in the neural control and regulation of the 811 
cutaneous vasculature and sweat glands. 812 
To date, the effect of MS on the thermoregulatory reflex has yet to be investigated.  813 
Therefore, the primary aim of this study was to test the hypothesis that individuals with MS will 814 
have impaired reflex control of sweating and skin blood flow to increases in core temperature 815 
(Tcore) via passive WBH, leading to diminished sweating and skin blood flow responses 816 
compared to matched healthy controls (CON).  Collected data, when combined with previous 817 
data, may also be able to provide insight into the origin of impairments (central vs. end-organ) in 818 
sweat glands and cutaneous blood vessels in individuals with MS. 819 
 820 
METHODS 821 
Subjects.  Individuals with definite relapsing-remitting MS (MS, n=18, expanded 822 
disability status scale, EDSS:  range 0-6) and age-, sex-, height-, weight-, and body surface area 823 
(BSA)-matched healthy controls (CON, n=18) voluntarily participated in this study.  Based on 824 
pilot data, an anticipated difference of approximately 0.45 mg/cm2/min in sweating between 825 
individuals with MS (n=4) and healthy controls (n=4) was expected (effect size = 1.47).  Six 826 
subjects per group was derived from a power analysis (a = 0.05, power = 0.80) to find an 827 
anticipated difference in SR between groups during WBH.  Due to the heterogeneity of 828 
symptomatology and disease course in individuals with MS, additional subjects were recruited. 829 
All individuals with MS were otherwise healthy, but clinically diagnosed and currently 830 
being treated by neurologists specializing in MS at the MS Clinic at the University of Texas 831 
Southwestern Medical Center.  This study focused on relapsing-remitting MS because it is the 832 
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most common disease course with ~85% of individuals with MS are initially diagnosed with this 833 
form of the disease (54).  This form of MS is characterized by acute attacks (exacerbations) 834 
followed by periods of partial or complete recovery (remissions) (54).  All individuals with MS 835 
were on disease-modifying therapies.  According to the 2015 consensus paper by the Multiple 836 
Sclerosis Coalition on the use of disease modifying therapies, FDA-approved disease-modifying 837 
treatment (DMT) is recommended and should be continued indefinitely (9).  Individuals with MS 838 
on symptom modifying therapies that are known to affect the CNS and/or thermoregulatory 839 
responses (i.e., anti-depressants, psychostimulants, anti-convulsants, anti-spasmatics, and anti-840 
cholinergics) were excluded from the study.  Individuals with MS remained on their DMT as 841 
prescribed by their neurologists, but were asked to refrain from taking any additional 842 
supplements and/or over-the-counter medications prior to testing.  All individuals with MS were 843 
tested during a stable phase of their disease, and were at least 6 months removed from their most 844 
recent relapse.  In effort to avoid any differences associated with acclimation status, healthy 845 
controls were tested during the same time of year and during the same time of day (9:00a-846 
12:00p) as their MS counterparts.  All procedures were approved by the Institutional Review 847 
Boards at Southern Methodist University (Dallas, TX, USA) and the University of Texas 848 
Southwestern Medical Center (Dallas, TX, USA), and all conformed to the Declaration of 849 
Helsinki.  All subjects were instructed on the protocol and provided their written informed 850 
consent prior to participation in the study. 851 
Instrumentation.  Internal temperature (Tcore) was assessed using an ingestible telemetry 852 
thermometry pill (HQ Inc., Palmetto, FL, USA) taken approximately 1-2 hours prior to the 853 
collection of baseline measurements.  Mean skin temperature (Tsk) was measured via the 854 
weighted average of 6 thermocouples attached to the skin (50).  Arterial blood pressure was 855 
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obtained via auscultation of the brachial artery (SunTech Medical Instruments, Raleigh, NC, 856 
USA).  Heart rate was identified using an electrocardiogram (ECG; Solar 8000i, General 857 
Electric, NY, USA) interfaced with a cardiotachometer (CWE, Ardmore, PA, USA).  Sweat rate 858 
was measured using capacitance hygrometry (Vaisala, Woburn, MA, USA) via the ventilated 859 
capsule method (6, 30) on a proximal and a distal site on the skin of the exposed dorsal forearm 860 
as used previously (13).  Laser Doppler flux (LDF; an index of skin blood flow) was measured at 861 
a proximal and a distal site on the skin of the exposed dorsal forearm positioned at heart level via 862 
integrated laser Doppler probes (PF413, Perimed, Ardmore, PA, USA) connected to a laser-863 
Doppler flowmeter (PF5010, Perimed).  Probes were fitted inside thermostatic probe holders 864 
(PF450, Perimed) connected to a local heating device (PF5020, Perimed) capable of controlling 865 
local skin temperature at that site.  For both SR and LDF, the mean values from the proximal and 866 
distal sites were averaged and recorded at each of the corresponding changes in Tcore of interest.  867 
To modify Tsk and Tcore, subjects were fitted in a tube-lined perfusion suit (Allen-Vanguard 868 
Technologies Inc., Ottawa, ON, Canada), allowing the manipulation of water temperature to 869 
provide a thermal stress, while leaving the instrumented forearm (as well as the head and feet) 870 
exposed for collection of LDF and SR data.  All measurements were taken from participants 871 
lying in the supine position on a patient bed. 872 
Protocol.  This study consisted of one experimental day lasting ~3.5 hours.  Baseline 873 
measurements were taken from the final minute of a 10-minute normothermic (NT) baseline 874 
period, in which 34 °C water perfused the tube-lined suit.  Following confirmation of adequate 875 
baseline measurements, whole-body heating was performed by circulating 48 °C water in the suit 876 
until an increase in Tcore of 0.8 °C was observed.  This moderate level of heat stress has been 877 
used in similar studies, and has been shown to be of sufficient magnitude to observe differences 878 
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in the neural control of skin blood flow and sweating (13, 32).  The following variables were 879 
continuously measured throughout the heating protocol:  Tcore, Tsk, heart rate, LDF, and SR.  880 
Upper arm cuff blood pressures were taken at 10 min intervals.  Since the suit was not in contact 881 
with the regions of skin where LDF and SR data were assessed, responses from these areas are 882 
presumed to be due entirely to thermoregulatory reflex-mediated neural modulation of efferent 883 
activity in response to changes in Tcore induced by the suit.  Upon achieving the desired increase 884 
in internal temperature (0.8 °C), Tcore was stabilized by lowering the temperature of the water 885 
perfusing the suit to 42 °C.  Once a stable elevated Tcore was established, WBH measurements 886 
were recorded before subjects were returned toward NT Tcore levels by decreasing the 887 
temperature of the water perfusing the suit to 16 °C.  During this time period, local heating in 888 
was performed at the sites of LDF collection on the forearm by setting thermostatic probe 889 
holders to 42 °C.  Local heating was terminated after observing a plateau in LDF values (~30 890 
minutes).  LDF was then normalized relative to peak vasodilation observed at 42 °C for each site. 891 
Data Analysis.  All data were continuously acquired at a sampling rate of 100 Hz on a 892 
16-channel data acquisition system (Biopac, Santa Barbara, CA, USA).  Mean values from all 893 
measured variables, with the exception of cuff blood pressure, were obtained from the final 894 
minute of NT and WBH.  Due to the dramatic increase in heart rate of 40-45% in both groups as 895 
a result of WBH, mean arterial pressure (MAP) during both NT and WBH was calculated using 896 
two different equations:  1) the traditional equation (MAPtrad=[systolic blood pressure-diastolic 897 
blood pressure÷3]+diastolic blood pressure), and 2) an adjusted equation (MAPadj) which applies 898 
mathematical weighting of systolic blood pressure based on the proportionally less time spent in 899 
systole (37).  Skin blood flow is reported as cutaneous vascular conductance (CVC) and 900 
calculated by dividing mean LDF values (arbitrary units; au) by MAP (both MAPtrad and 901 
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MAPadj) calculated from brachial artery auscultation.  CVC data was also normalized to peak 902 
vasodilation obtained during the final minute of local heating at 42 °C for 30 minutes and 903 
expressed as percentage of peak CVC (%CVC42C).  Change in these variables relative to NT 904 
baseline conditions are plotted as mean change ± standard deviation. 905 
Statistical Analysis.  All values are presented as mean ± standard deviation.  A two-way 906 
repeated measures ANOVA was utilized to compare SR of groups (MS vs CON) as a function of 907 
Tcore (0.1 °C increments).  Due to the necessity for estimations of MAP in order to calculate 908 
CVC, it was not possible to appropriately calculate CVC as a function of Tcore.  A two-way 909 
repeated measures ANOVA was utilized to compare LDF responses (au) of groups (MS vs. 910 
CON) as a function of Tcore (0.1 °C increments) was utilized to observe the response profile of 911 
LDF.  Post-hoc multiple comparisons were performed utilizing paired t-tests with a Bonferroni 912 
adjustment.  Paired t-tests were performed on ∆ CVC from baseline as a result of WBH (0.8 °C 913 
increase in Tcore) and local heating responses.  For any significant differences between groups, an 914 
effect size (Cohen’s d) was calculated to provide practical significance.  All analysis was 915 
conducted using IBM SPSS version 23 (IBM, Armonk, NY, USA), and plotted via GraphPad 916 




Subject Characteristics 921 
Subject characteristics for both groups are presented in Table 1.  The ranges for 922 
individuals with MS and CON were as follows:  age-(MS: 28-54; CON: 28-53 yrs), height-( MS: 923 
152-193; CON: 160-196 cm), weight-(MS: 48.2-102.9; CON: 48.2-93.1 kg), body surface area-924 
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(MS: 1.46-2.34; CON: 1.53-2.26 m2) and body mass index-(MS: 17.6-35.2; CON: 17.1-30.0 925 
kg/m2).  All individuals with MS were diagnosed with relapsing-remitting MS 14±4 years prior 926 
to participation in the study.  Disease-modifying treatments used by individuals with MS 927 
included the following: Avonex (interferon beta-1a), n=1; Gilenya (fingolimod), n=3; Copaxone 928 
(glatiramer acetate), n=3; Tecfidera (dimethyl fumarate), n=4; Tysabri (natalizumab), n=5; 929 
Plegridy (peginterferon beta-1a), n=1; no DMT, n=1. 930 
Normothermic Baseline 931 
Baseline heart rate was significantly greater in the control group (CON: 72±16; MS: 932 
65±7 bpm, p=0.19), while baseline systolic (CON: 115±12; MS: 108±13 mmHg, p=0.13), 933 
diastolic (CON: 74±8; MS: 70±10 mmHg, p=0.26), MAPtrad (CON: 88±9; MS: 83±11 mmHg, 934 
p=0.17) and MAPadj (CON: 88±9; MS: 83±11 mmHg, p=0.15) were similar between groups. 935 
Additionally, there were no group differences in Tcore (CON: 37.1±0.3; MS: 37.2±0.3 °C, 936 
p=0.22), Tsk (CON: 35.1±0.4; MS: 34.9±0.5 °C, p=0.12), SR (CON: 0.11±0.02; MS: 0.10±0.03 937 
mg/cm2/min, p=0.16).  All indices of skin blood flow were similar during NT baseline: LDF 938 
(CON: 18±8; MS: 17±7 au, p=0.60), mean CVCtrad (CON: 0.20±0.09; MS: 0.20±0.08 au/mmHg, 939 
p=0.98), mean CVCadj (CON: 0.20±0.09; MS: 0.20±0.08 au/mmHg, p=0.96), %CVC42C:trad 940 
(CON: 9.1±5.1; MS: 7.7±3.2, p=0.32), or %CVC42C:adj (CON: 9.1±5.1; MS: 7.8±3.2, p=0.38). 941 
Heat Stress 942 
Hemodynamic responses, represented as change from baseline, to WBH are presented in 943 
Table 2.  During the last minute of WBH, heart rate (CON: 100±16; MS: 95±14 bpm, p=0.44), 944 
while diastolic blood pressure (CON: 69±9; MS: 66±5 mmHg, p=0.14).  Interestingly, although 945 
systolic blood pressure following heat stress was not statistically different (CON: 125±15; MS: 946 
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115±17 mmHg, p=0.09), MAPtrad (CON: 88±8; MS: 83±8 mmHg, p=0.08) and MAPadj (CON: 947 
92±8; MS: 86±10 mmHg, p=0.06) trended higher in the CON group. 948 
Thermoregulatory responses, represented as change from baseline, to WBH are presented 949 
in Figures 1-3.  Of importance, a large effect size (d=0.81 and d=1.01) for SR differences 950 
between groups was observed at ∆ Tcore 0.7 °C and 0.8 °C, respectively.  During the final minute 951 
of WBH, the maximal SR achieved by individuals with MS was significantly lower than that of 952 
CON (CON: 0.76±0.27; MS: 0.52±0.18 mg/cm2/min, p=0.003).  Tcore (CON: 37.9±0.3; MS 953 
38.0±0.2 °C, p=0.20), Tskin (CON: 38.6±0.5; MS: 38.7±0.5 °C, p=0.50), LDF (CON: 109±38; 954 
MS: 106±28, p=0.92), CVCtrad (CON: 1.3±0.4; MS: 1.3±0.5 au/mmHg, p=0.55), CVCadj (CON: 955 
1.2±0.4; MS: 1.2±0.5 au/mmHg, p=0.79), %CVC42C:trad (CON: 53±17; MS: 47±14, p=0.41), and 956 
%CVC42C:adj (CON: 51±16; MS: 45±14, p=0.30) were similar during the final minute of heating. 957 
Local Heating 958 
 Peak LDF responses to 42 °C local heating are presented in Figure 4.  In short, there were 959 
no significant differences in any peak values for LDF (p=0.41), CVC42C:trad (p=0.32), or 960 
CVC42C:adj (p=0.32). 961 
 962 
DISCUSSION 963 
The present study is the first to provide evidence of impairments of thermoregulatory 964 
reflex sweating in individuals with MS during passive WBH.  Confirming our hypothesis, 965 
sweating responses were blunted in individuals with MS during a moderate increase in core 966 
temperature compared to healthy controls.  Individuals with MS had significantly reduced sweat 967 
rates as a function of core temperature and this difference increased as temperature increased.  968 
Counter to our hypothesis, the reflex control of the cutaneous vasculature (represented as 969 
 46 
%CVC42C) appears to be preserved in individuals with MS, as increases in skin blood flow were 970 
similar between individuals with MS and healthy controls.  Taken together, these findings 971 
indicate that MS impairs the reflex control of thermoregulatory responses to passive heat stress. 972 
The thermoregulatory reflex requires complex integration of afferent and efferent signal 973 
processing.  Upon exposure to a rising core temperature, thermoreceptors at the skin and the core 974 
provide afferent information that is relayed to the preoptic area of the hypothalamus 975 
(thermoregulatory center of the brain) (21, 45).  Once integrated, it is thought this brain center 976 
modulates heat dissipation via increasing autonomic signaling to thermoregulatory effector 977 
organs (i.e., cutaneous vasculature and sweat glands).  The observed reduction in the neural 978 
control of sweating in the MS group provides evidence of autonomic impairments as a result of 979 
the disease.  The mechanisms responsible for this are not readily apparent.  With MS being an 980 
autoimmune disease affecting the CNS, it is probable that neural conduction within the brain and 981 
spinal cord plays a pivotal role in the blunted SR responses observed in this study.  As previously 982 
mentioned, reduction in myelin (the underlying pathophysiology of MS) has detrimental effects 983 
on neural conduction.  Reduced conduction velocity, impaired saltatory conduction, and 984 
increased incidence of conduction block stems from inadequate insulation properties that are 985 
typically provided by an intact myelin sheath (19).  Reduced myelin cross sectional area, thus 986 
increased axonal exposure, leads to decreases in the current available relative to the current 987 
required for signal propagation (i.e., axonal “safety factor”).  Therefore, it remains possible that a 988 
dampening of the signal for sweating, impaired integration of the signal for sweating, and/or the 989 
efferent signal being relayed from the CNS occurs in MS.  Additionally, the increased axonal 990 
exposure as a result of decreased myelin cross sectional area increases the relative reliance on 991 
voltage-gated sodium and potassium channels responsible for signal transmission down 992 
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demyelinated areas of the axon.  Over time, this increased voltage-gated channel reliance 993 
ultimately leads to increased expression of sodium channels at exposed demyelinated sites (46, 994 
47), in effort to ensure action potential propagation.  While this adaptation along the axon may 995 
be beneficial for maintaining conduction during normothermic resting conditions, it is thought 996 
that these sodium channels are temperature sensitive (19), potentially altering neural 997 
signaling/processing within the CNS when internal temperature is increased.  Upon relatively 998 
modest increases in Tcore (~0.2-0.5 °C), these temperature-sensitive sodium channels close, thus 999 
terminating the depolarization phase of subsequent action potentials (18, 19).  Although not 1000 
directly tested in this study, it is likely this adaptation contributed to the observed reduction in 1001 
reflex-mediated sweating responses observed herein. 1002 
In the present investigation, the magnitude of increase in SR was blunted during passive 1003 
WBH.  Altered control of sweating in individuals with MS has been identified previously (7, 38, 1004 
41).  Initially, investigators used the technique of staining the skin of participants with quinizarin 1005 
powder, before increasing their body temperature via passive heating (37, 51).  Quinizarin 1006 
powder, initially yellow in color, stains to a dark shade of purple when in contact with moisture 1007 
(i.e., perspiration).  The use of this technique allows for visual inspection of sweating 1008 
abnormalities, but lacks the ability to quantify sweating responses (qualitative only 1009 
measurement).  More recently, using more quantifiable methods, peripheral sweat gland 1010 
dysfunction has since been identified (14).  In this study, Davis, et al. (14) demonstrated that 1011 
postganglionic sympathetic nerves and sweat glands were responsive to maximal peripheral 1012 
cholinergic stimulation in individuals with MS.  However, individuals with MS demonstrated a 1013 
diminished ability to sweat (decreased output per sweat gland) despite similar sweat gland 1014 
recruitment in comparison to healthy counterparts.  As a follow-up study, Davis et al. (14) 1015 
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addressed the potential for decreases in sweat function being attributed to detraining or de-1016 
adaptation in this clinical population by exercise training a cohort of MS patients.  Expected 1017 
improvements in sweating responses (e.g., increases in maximal sweating) following aerobic 1018 
exercise training previously demonstrated in healthy individuals (10, 52) were not observed in 1019 
individuals with MS, suggesting impairments in thermoregulatory control.  Given these findings, 1020 
the current study utilized a passive WBH stress model to investigate sweating responses on an 1021 
exposed forearm, to target thermoregulatory reflex-mediated modulation of efferent activity in 1022 
response to changes in Tcore.  In agreement with aforementioned studies, the findings of the 1023 
current study provide further evidence of sweating impairments, and suggest these impairments 1024 
could be attributed to altered neural control of sudomotor function.  Taken together, MS 1025 
impairments in sudomotor control within the CNS are complex and could be attributed to 1026 
interactions of one or more of the following:  1) altered sensory processing, 2) neural integration 1027 
abnormalities within the CNS, and/or 3) inappropriate end-organ effector processing.  1028 
Ultimately, these alterations of neural function could lead to end-organ maladaptations in the 1029 
sweat glands themselves including a down-regulation of cholinergic receptors (number and/or 1030 
sensitivity) on the eccrine sweat gland, which would ultimately result in lower sweating 1031 
responses per quanta acetylcholine released and/or atrophy of sweat glands themselves. 1032 
The finding of preserved cutaneous vascular function in individuals with MS in response 1033 
to an increase in Tcore is an interesting one.  The %CVC42C:adj values from the groups in this 1034 
study, which align well with values reported in a similar study (13), showed no apparent 1035 
differences at any Tcore value.  This suggests that not only is the control of the cutaneous 1036 
vasculature in MS similar to controls in response to heat stress, but sweating and skin blood flow 1037 
may potentially be under separate neural control.  However, it also remains possible that the 1038 
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change in Tcore utilized in this study was not severe enough to reveal significant cutaneous 1039 
vascular impairment.  For healthy participants, in response to light exercise (~30% VO2max), Tcore 1040 
increases nearly 0.8 ºC, while increases in Tcore of ~1.5 ºC and 2.0 ºC are seen with moderate 1041 
(~51% VO2max) and moderate-high (~70% VO2max) exercise intensities, respectively (43).  1042 
Additionally, in a study by Low et al. investigating more severe levels of heat stress in healthy 1043 
participants (~∆ 1.5 ºC Tcore), the authors demonstrated that CVC, skin sympathetic nerve 1044 
activity (SSNA) and muscle sympathetic nerve activity (MSNA) increase as a function of Tcore 1045 
(32).  This increase in SSNA as a result of WBH was likely attributed to activation of sweat 1046 
glands and increasing dilation of the cutaneous vasculature (i.e., increasing CVC) to facilitate 1047 
heat dissipation.  Although in the current study, differences in %CVC42C:adj responses to a 1048 
passive heat stress that elicits an 0.8 ºC change in Tcore were not apparent between groups, 1049 
potential differences could possibly be revealed at higher levels of heat stress in which more 1050 
autonomic activity is required.  However, a modest change (∆ 0.8 ºC) in Tcore was chosen in the 1051 
current study in effort to elicit measureable SR and LDF responses while avoiding the onset 1052 
and/or minimizing symptomatology associated with Uhthoff’s phenomenon.  Further research is 1053 
warranted to investigate the neural control of the cutaneous vasculature at higher Tcore levels in 1054 
individuals with MS.  Being that thermoregulatory reflexes utilize post-ganglionic nerves to 1055 
induce both vasodilation and sweating, it is perplexing that SR response are blunted, while 1056 
seemingly leaving the control of skin blood flow intact.  Clearly more research is needed to 1057 
elucidate these observations and overlying mechanisms. 1058 
In this investigation, blunted reflex control of sweating in MS was apparent at relatively 1059 
moderate increases in Tcore (~0.8 °C), while control of skin blood flow remained intact.  These 1060 
levels of elevated Tcore are likely encountered on a daily basis among most individuals, and lie 1061 
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within the minimum core temperatures necessary to elicit Uhthoff’s phenomenon.  Since the 1062 
evaporation of sweat is the most effective form of heat dissipation among humans, suppressed 1063 
control of this mechanism is particularly detrimental to individuals with MS.  The disease likely 1064 
renders them unable to adequately prevent gaining heat (increased Tcore) via blunting of sweating 1065 
responses.  The combination of heat sensitivity (Uhthoff’s phenomenon) and apparent 1066 
thermoregulatory dysfunction creates a vicious cycle for individuals vulnerable to excess rises in 1067 
Tcore, with known heat intolerance. 1068 
Limitations & Future Considerations 1069 
 Although our findings are consistent with CNS impairments (1, 19, 38, 51), it remains 1070 
possible that our results were influenced by DMT prescribed to individuals with MS.  Patients 1071 
were carefully screened for additional medications (i.e., anti-depressants, psychostimulants, anti-1072 
convulsants, anti-spasmatics, and anti-cholinergics), and precautions were taken to remove any 1073 
clear outliers that may influence group data.  With this in mind, immediate prescription of DMT 1074 
upon diagnosis is the current standard of care (9), thus a critical understanding of individuals 1075 
with MS currently on these medications is warranted. 1076 
 CVC data from the current study are referenced to non-noxious local skin heating to 42 1077 
ºC (25).  It may be possible that further vasodilation could have occured at higher, potential 1078 
noxious, local heating temperatures (e.g., 43-46 ºC).  Cutaneous nociceptors robustly express 1079 
transient receptor-potential vanilloid type-1 (TRPV1) channels (49), which are necessary in the 1080 
heat-pain pathway (8, 12).  These receptors are stimulated at temperatures < 42 °C (3) even if not 1081 
consciously processed as pain in normal healthy participants, individuals with MS present with 1082 
somatosensory abnormalities (e.g., reduction in skin temperature detection thresholds) and 1083 
central pain (with incidence rates of 50-55%) which could make higher temperatures more 1084 
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noxious (31).  Thus, to avoid a potential noxious stimulus and collateral physiological responses, 1085 
a 42 °C local heating protocol was utilized (25).  Additionally, as part of the thermoregulatory 1086 
reflex, elevated local skin temperatures can increase sweat output to aid in heat loss.  Since local 1087 
skin temperature at the SR measurement site was not recorded in the current study, it remains 1088 
possible that there could be local influences aiding in the responses seen here.  That being said, 1089 
the autonomic control of local skin temperature is part of the thermoregulatory reflex and would 1090 
only serve to strengthen our findings based on these results. 1091 
The use of perfusion suits to induce a tightly controlled passive heat stress limits the 1092 
ability to assess certain aspects of thermoregulatory function.  By covering ~85% of BSA, this 1093 
heat stress technique effectively reverses skin heat transfer covered by the suit to that of an 1094 
“outside-in” direction rather than “inside-out”.  Although there are circumstances in which 1095 
humans can face this form of heat stress, the majority of physiological heat stress is encountered 1096 
from increases in metabolism (i.e., physical activity).  To fully understand the impact of impaired 1097 
sweating in MS on heat dissipation, further research is needed using exercise as an experimental 1098 
paradigm to increase core temperature.  Finally, the experimental design required subjects be 1099 
positioned in the supine position.  Many heat stresses experienced by individuals with MS 1100 
involve exposures or activity in the upright position.  This may be doubly problematic to these 1101 
patients as current data suggest that dysautonomia may also manifest itself with the control of 1102 
arterial blood pressure (23, 27). 1103 
  1104 
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Conclusion 1105 
 This study utilized a novel approach to examine the reflex control of thermoregulatory 1106 
responses to a passive heat stress in individuals with MS.  These results demonstrate individuals 1107 
with MS attenuated increases in SR, leading to suppressed SR in response to moderate increases 1108 
in Tcore.  Furthermore, it appears that MS does not affect the reflex control of the cutaneous 1109 
vasculature in response to moderate elevations in Tcore.  These findings are particularly troubling 1110 
for individuals with MS, as this altered reflex control of thermoregulatory responses could 1111 
contribute to decreased heat loss capacity.  This apparent thermoregulatory dysfunction can 1112 
compound heat intolerance (Uhthoff’s phenomenon), which may result in increased frequency 1113 
and susceptibility to this acutely debilitating symptomatology.  Further research is warranted to 1114 
determine whether this attenuated reflex control translates to thermoregulatory dysfunction, 1115 
especially during physical activity. 1116 
  1117 
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Table 1.  Subject characteristics 
 
 MS (n=18) CON (n=18) p-value 
Age (yrs) 41 ± 7 39 ± 8 0.32 
Weight (kg) 72 ± 17 70 ± 14 0.68 
Height (cm) 169 ± 11 172 ± 10 0.50 
BMI (kg/m
2
) 24.8 ± 4.3 23.6 ± 3.2 0.51 
BSA (m
2
) 1.8 ± 0.3 1.8 ± 0.2 0.86 
 
BMI, body mass index; BSA, body surface area. 
   1266 





Figure 1.  Mean change in sweat rate (∆ SR) from baseline (±SD) as a function of changes in 1271 
core temperature (∆ Tcore) during passive whole-body heating (panel A); and mean group (bars) 1272 
and individual summary data (small squares) showing ∆ SR from baseline following a 0.8 ºC 1273 
increase in Tcore  (panel B) in persons with multiple sclerosis (MS) and healthy controls (CON).  1274 
*Differences observed at 0.7 ºC and 0.8 ºC (Bonferroni-adjusted p < 0.05). 1275 
 1276 
 1277 
Figure 2.  Mean change in laser-Doppler flux (LDF; arbitrary units) from baseline (±SD) as a 1278 
function of changes in core temperature (∆ Tcore) during a whole-body heat stress in individuals 1279 
with multiple sclerosis (MS) and healthy controls (CON). 1280 
 1281 
 1282 
Figure 3.  Mean group (bars) and individual (small squares) changes in peak cutaneous vascular 1283 
conductance (∆ CVC42C:adj) from baseline during passive whole-body heating in individuals with 1284 
multiple sclerosis (MS) and healthy controls (CON). 1285 
 1286 
 1287 
Figure 4.  Mean group (bars) and individual (small squares) responses in peak heart rate adjusted 1288 
cutaneous vascular conductance (CVC42C:adj; panel A), peak traditionally calculated cutaneous 1289 
vascular conductance (CVC42C:adj:trad; panel B), and peak absolute laser-Doppler flux (LDF; panel 1290 
C) values during the final minute of local heating to 42 ºC in individuals with multiple sclerosis 1291 
(MS) and healthy controls (CON). 1292 
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CHAPTER 3 1308 
 1309 
 1310 
Does MS impair the ability to control core temperature through sweat and increasing skin 1311 




The findings from Chapter 2 demonstrate clear impairments in thermoregulatory reflex increases 1316 
in sweat rate but not skin blood flow during a passive heat stress.  While this technique is a 1317 
powerful tool for investigating the thermoregulatory reflex, the use of a perfusion suit creates an 1318 
artificial environment in which humans would rarely encounter.  Using a passive heating suit the 1319 
body remains encapsulated and thus, relatively unable to dissipate heat from the skin’s surface to 1320 
the environment.  Additionally, a passive heat stress does not allow for the assessment of 1321 
“thermoregulatory function”, as researchers (via the suit) primarily dictate the rise in the 1322 
participant’s body temperature.  Therefore, in order to assess the control of body temperature 1323 
(i.e., thermoregulatory function) in MS compared to CON, research should be conducted under 1324 
conditions that permit heat dissipation from the skin’s surface as it occurs under normal 1325 
conditions.  Therefore, the following study used dynamic exercise to induce a heat stress in an 1326 
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ABSTRACT 1365 
Impairments in sudomotor function during passive whole-body heating have been reported in 1366 
multiple sclerosis (MS), a demyelinating disease of the CNS that disrupts autonomic function.  1367 
However, the capability of the thermoregulatory system to control body temperature during 1368 
exercise has never been assessed in MS.  Thus, the aim of the present study was to test the 1369 
hypothesis that thermoregulatory function is impaired in MS patients compared to healthy 1370 
controls (CON) at a fixed metabolic heat production.  Sweating and skin blood flow responses 1371 
were compared between 12 individuals diagnosed with relapsing-remitting MS (9 females, 3 1372 
males) and 12 matched healthy controls during a single bout of cycling exercise (metabolic heat 1373 
production of ~4.5 W/kg) for 60 min in a climate-controlled room (25 °C, 30% RH).  Individuals 1374 
with MS exhibited an attenuated increase in cumulative whole-body sweat loss after 30 min 1375 
(CON: 104 ± 37; MS: 72 ± 51 g, p=0.04) and 60 min (CON: 285 ± 62; MS: 209 ±94 g, p=0.02), 1376 
as well as lower sweating thermosensitivity (CON: 0.84±0.44; MS: 0.53±0.27 mg/cm2/min/°C, 1377 
p=0.05).  Despite evidence for thermoregulatory dysfunction, there were no differences between 1378 
MS and CON in esophageal or rectal temperatures at 30 or 60-minute time points (p>0.05).  1379 
Cutaneous vasculature responses were also not different in MS compared to CON (p>0.05).  1380 
Taken together, MS blunts sweating responses during exercise while cutaneous vasculature 1381 
responses are preserved.  Altered mechanisms of body temperature regulation in persons with 1382 
MS may lead to temporary worsening of disease symptoms and limit exercise tolerance under 1383 
more thermally challenging conditions. 1384 
1385 
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NEW AND NOTEWORTHY 1386 
 This study was the first to assess thermoregulatory function during dynamic exercise in 1387 
individuals with MS.  The novel findings are 3-fold: 1) individuals with MS had blunted WBSL 1388 
responses to exercise of a similar heat production compared to CON as well as a blunted 1389 
relationship between increases in mean body temperature and local sweat rate (i.e., 1390 
thermosensitivity); 2) despite these indices of thermoregulatory dysfunction, individuals with 1391 
MS were able to achieve similar steady-state local sweat rates, Teso, Trec as healthy CON; and 3) 1392 
confirming previous findings, the control and function of the cutaneous vasculature remains 1393 
comparable MS versus CON.  Taken together, there is clear evidence of abnormal sweating 1394 
responses in MS, however in the relatively modest heat loads imposed in this study it appears the 1395 
impact of these abnormalities is not readily apparent.  1396 
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INTRODUCTION 1397 
Multiple sclerosis (MS) is the most disabling neurological disorder of young adults (60).  1398 
The pathophysiology of MS is principally described as a progressive deterioration and loss of 1399 
functional capabilities as a result of myelin destruction and axonal loss with in the central 1400 
nervous system (CNS) (20, 33, 54).  Dysfunction along the axon can lead to a myriad of 1401 
symptoms (e.g., fatigue, gait difficulties, numbness/tingling, visual dysfunction, depression, 1402 
cognitive changes etc.) and has been shown to cause autonomic dysfunction (1, 2, 4, 5, 18, 29, 1403 
34, 39, 48, 50, 56) with indications of thermoregulatory abnormalities (5, 14, 22, 40, 47); 1404 
however most of these studies utilize subjective “sweat tests” by clinicians with no concern for 1405 
body temperature regulation.  Adding complexity, it is well documented that a majority of MS 1406 
patients are subject to a reversible temporary worsening of their symptoms with increases in core 1407 
temperature, known as Uhthoff’s phenomenon (58).  It remains unknown if individuals with MS 1408 
are capable of appropriately activating thermo-effector countermeasures to prevent excessive 1409 
elevations in core temperature during thermal stress, and thus symptom worsening.  1410 
In healthy humans, an increase in body temperature causes an increase in cutaneous 1411 
blood flow and the secretion of sweat from eccrine sweat glands to augment radiative, 1412 
convective and evaporative heat loss from the skin to the surrounding environment, a process 1413 
known as the thermoregulatory reflex.  Recently, our lab utilized a passive heat stress protocol to 1414 
examined thermoregulatory control of sweating and cutaneous vascular conductance (CVC, an 1415 
index of skin blood flow) in MS (3).  This study demonstrated that individuals with relapsing-1416 
remitting MS had attenuated increases in sweat rate, but not CVC in response to passive 1417 
increases in core temperature.  While the aforementioned findings clearly indicate a 1418 
compromised autonomic thermoregulatory reflex in MS, encapsulation of the body by the 1419 
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perfusion suit used in the study does not allow for any meaningful disparity in evaporative or dry 1420 
heat exchange from most of the body, thus limiting our ability to assess the practical impact of 1421 
these thermoregulatory deficits on the prevailing heat strain with MS. 1422 
It remains unknown if the attenuated sweat rates observed in our previous study translate 1423 
to an impaired regulation of body temperature (i.e., thermoregulatory function) in a non-1424 
encapsulated, practical setting which allows heat dissipation from the body to the environment to 1425 
be freely modified by differences in sudomotor and/or vasomotor responses.  Therefore, the aim 1426 
of this study was to test the hypothesis that individuals with MS will: 1) exhibit heightened 1427 
increases in Tcore during exercise of a fixed heat production compared to age-, height-, mass-, and 1428 
sex-matched healthy controls; and 2) these elevations in Tcore will likely be attributed to reduced 1429 
potential for evaporative heat loss owing to attenuated sweating during exercise compared to 1430 
healthy controls.  Additionally, although sudomotor dysfunction is expected, we hypothesize that 1431 




 Individuals with definite relapsing-remitting MS [MS, n=12 (9 females, 3 males), 1436 
expanded disability status scale, EDSS:  range 0-6] and age-, sex-, height-, and weight-matched 1437 
healthy controls [CON, n=12 (9 females, 3 males)] voluntarily participated in this study.  From 1438 
pilot data of 6 (3 MS, 3 CON) subjects, a power calculation (G*power version 3.1.9.3) with  1439 
set to 0.8 and  at 0.05, a minimum sample size of 16 subjects (8 MS, 8 CON) were required 1440 
based on group mean WBSL values (MS: 160 ± 106 g; CON: 281 ± 66 g, effect size: d= 1.37).  1441 
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In effort to account for the heterogeneity of disease status in MS, additional subjects were 1442 
recruited for the study. 1443 
 All individuals with MS were otherwise healthy, but clinically diagnosed and currently 1444 
being treated by neurologists specializing in MS at the MS Clinic at the University of Texas 1445 
Southwestern Medical Center.  This study focused on relapsing-remitting MS because it is the 1446 
most common disease course with ~85% of individuals with MS initially diagnosed with this 1447 
form of the disease (54).  This form of MS is characterized by acute attacks (exacerbations) 1448 
followed by periods of partial or complete recovery (remissions) (54).  All individuals with MS 1449 
were on disease-modifying therapies.  According to the 2015 consensus paper by the Multiple 1450 
Sclerosis Coalition on the use of disease modifying therapies, FDA-approved disease-modifying 1451 
treatment (DMT) is recommended and should be continued indefinitely (9).  Individuals with MS 1452 
on symptom modifying therapies that are known to affect the CNS and/or thermoregulatory 1453 
responses (i.e., anti-depressants, psychostimulants, anti-convulsants, anti-spasmatics, and anti-1454 
cholinergics) were excluded from the study.  Individuals with MS remained on their DMT as 1455 
prescribed by their neurologists but were asked to refrain from taking any additional supplements 1456 
and/or over-the-counter medications prior to testing.  All individuals with MS were tested during 1457 
a stable phase of their disease and were at least 6 months removed from their most recent relapse. 1458 
 All subjects were non-smokers and had no history of metabolic, pulmonary, or 1459 
cardiovascular disease.  Subjects refrained from caffeine, alcohol, and vigorous exercise 24 h 1460 
prior to the trial.  All trials took place between 07:00-11:00 a.m. to avoid potential effects of 1461 
circadian rhythm and outside of summer months in an effort to avoid any differences associated 1462 
with acclimation status.  All experimental procedures and protocols conformed to the 1463 
Declaration of Helsinki and were approved by the Institutional Review Board at Southern 1464 
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Methodist University.  All subjects provided written consent prior to volunteering to participate 1465 
in the study. 1466 
Instrumentation and Measurements 1467 
Thermometry:  Rectal temperature (Trec) was measured using a sterile thermocouple 1468 
probe (Mon-a-Therm 400TM, Covidien, Manfield, MA) inserted a minimum of 12 cm past the 1469 
anal sphincter in all 24 subjects.  Esophageal temperature (Teso) was measured by placing a 1470 
sterile thermocouple probe (Mon-a-Therm 400TM, Covidien, Manfield, MA) through the 1471 
subject’s nostril into the esophagus.  The location of the esophageal probe was estimated to be at 1472 
the level of the eighth and ninth thoracic vertebrae, reflecting the region nearest to the left 1473 
ventricle and aorta (35).  Teso measurements were only collected in 7 matched-pairs (MS vs 1474 
CON) due to the inability for some individuals with MS to tolerate the thermocouple placement.  1475 
Skin temperatures were collected at 8 points (forehead, acromion, scapula, triceps, hand, 1476 
abdomen, quadriceps, calf) using wireless temperature sensing buttons (iButton DS1922L; 1477 
Embedded Data Systems, Lawrenceburg, KY) attached using surgical tape (Transpore; 3M, 1478 
London, Ontario, Canada) and collected every 5 s before being exported to a personal computer 1479 
to be subsequently analyzed.  Mean skin temperature (Tsk) was estimated using 6-site weighted 1480 
average as described elsewhere (31, 57). 1481 
 Sweat data.  Body mass was measured in triplicate at 15-minute intervals during the 1482 
experimental protocol using a precision scale with an accuracy of ±2 g (Sartorius Combics 2, 1483 
Goettingen, Germany). Whole-body sweat loss (WBSL) was determined as the change in body 1484 
mass from baseline minus respiratory vapor exchange and metabolic mass losses (36).  Local 1485 
sweat rate (LSR) was collected continuously throughout the exercise protocol at the upper back 1486 
and forearm using capacitance hygrometry (Vaisala HMT333, Helinski, Finland) via the 1487 
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ventilated capsule method (8, 32).  LSR was expressed as mean sweat rate averaged from both 1488 
collection sites.  Additionally, sweat gland recruitment was quantified using iodine-stained 1489 
resume 100% cotton paper (Southworth 24 lb. Resume paper, Agawam, MA) printed with a 2x2 1490 
cm grid placed on the skin for ~30 s.  Following the trial, this paper was immediately scanned 1491 
(EPSON Perfection V6000, Owa, Suwa, Nagano, Japan) and quantified via hand-counting each 1492 
stained marking and validating it using a free online imaging software provided by NIH (ImageJ, 1493 
NIH) described elsewhere (14, 24). 1494 
 Metabolic data:  Estimates for metabolic energy expenditure were determined via 1495 
indirect calorimetry using a metabolic cart (Parvomedics TrueOne 2400, Sandy, UT).  Subjects 1496 
were instrumented with a mouthpiece and nose clip, while expired gases were continuously 1497 
collected throughout exercise and analyzed in 1-minute increments. 1498 
 External work rate (W) was regulated and measured using an electronically-braked semi 1499 
recumbent cycle ergometer (Lode Corival, AEI Technologies, Naperville, IL.).  Estimations of 1500 
heat production based on body mass and surface area were expressed by dividing the difference 1501 
between M and external work (M-W= Hprod) in watts by kilograms of body mass (W/kg) and 1502 
body surface area (W/m2), respectively. 1503 
 Hemodynamic data:  Blood pressure (BP) was collected every 5 min via automated 1504 
brachial artery auscultation (SunTech, Medical Instruments, Raleigh, NC, USA).  Heart rate 1505 
(HR) was continuously monitored using a standard lead II surface ECG (Solar 8000i, General 1506 
Electric, NY, USA) interfaced with a cardiotachometer (CWE, Ardmore, PA, USA).  Skin blood 1507 
flow, indexed as laser-Doppler flux (LDF), was collected on the upper back and forearm using 1508 
integrated laser-Doppler probes (PF413, Perimed, Ardmore, PA, USA) connected to a laser-1509 
Doppler flowmeter (PF5010, Perimed, Ardmore, PA, USA).  Probes were fitted inside 1510 
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thermostatic probe holders (PF450, Perimed, Ardmore, PA, USA) connected to a local heating 1511 
device (PF5020, Perimed, Ardmore, PA, USA) capable of controlling local skin temperature at 1512 
that site. 1513 
Protocol 1514 
 Exercise Intensity:  The selection of exercise intensity was based on two criteria: 1) the 1515 
workload selected should be sufficient to elicit significant increases in Tcore, while being modest 1516 
enough for most individuals with MS to complete the entire 60-minute trial; 2) the exercise 1517 
intensity was chosen to elicit a similar amount of absolute metabolic heat production (Hprod) 1518 
between an MS individual and their CON match, as described in previous studies (12, 27, 55).  1519 
In short, an absolute external workload of 70 watts was initially assigned to all individuals to 1520 
elicit ~400 watts of absolute metabolic heat production (assuming ~17% efficiency for semi-1521 
recumbent cycling based on pilot data) for comparisons of whole-body sweat loss (WBSL).  1522 
Since MS individuals were tightly matched to CON of similar characteristics, this fixed 1523 
metabolic heat load was also a similar relative metabolic heat production on a W/kg and W/m2 1524 
basis.  If individuals deviated from this Hprod value (chosen a priori), workloads were adjusted 1525 
accordingly in effort to consistently maintain Hprod at ~400 W. 1526 
 Experimental Protocol:  Following completion of consent and medical history 1527 
documents, each subject provided a urine sample, which was immediately analyzed for urine-1528 
specific gravity (USG) using a refractometer (Atago Pocket Refractometer, Kobe, Hyogo-ken, 1529 
Japan), to ensure pre-exercise euhdyration and that pre-exercise hydration status was similar 1530 
between groups.  A USG cutoff value of 1.020 was enforced as values below this threshold have 1531 
been suggested to indicate euhydration (30).  Following confirmation of euhydration, subjects 1532 
then changed into standard athletic clothing (running shorts, socks, and shoes), and were then 1533 
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instrumented with the aforementioned measurements outlined above.  Following 1534 
instrumentation, baseline body mass measurements were taken while fully instrumented.  Next, 1535 
subjects were seated on a semi-recumbent cycle ergometer (Lode Corival, Groningenthe, 1536 
Netherlands) in a climate-controlled room (Cantrol Environmental Systems Ltd., Markham, ON, 1537 
CA) set to 25°C 35% RH and asked to rest comfortably for 3 min of baseline measurements.  1538 
Then, subjects began cycling at a cadence of 60 to 80 rpm at an external workload of 70 W of 1539 
resistance.  At 15-minute intervals throughout the exercise protocol, subjects stopped cycling and 1540 
stepped on the adjacent scale for triplicate measures of body mass (fully instrumented).  Once 1541 
stable body mass measurements were collected (no longer than 2 min), subjects resumed cycling.  1542 
Following the final weigh-in at 60 min, subjects returned to their seat on the cycle ergometer for 1543 
the local heating period, lasting 30 min.  Neither food nor fluid were ingested during the 1544 
experimental protocol. 1545 
Data Analysis 1546 
All data were continuously acquired at a sampling rate of 100 Hz on a 16-channel data 1547 
acquisition system (Biopac, Santa Barbara, CA, USA).  Mean values from all measured variables 1548 
were obtained from the final minute of each 15-minute period during exercise.  Rate of metabolic 1549 
energy expenditure (M) was calculated using steady-state values for oxygen consumption (VO2) 1550 
in liters per minute and respiratory exchange ratio (RER) during exercise using the following 1551 
equation (12, 45):  1552 
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where ec is the caloric equivalent per liter of oxygen for the oxidation of carbohydrates (21.13 1553 
kJ/L), and ef is the caloric equivalent representing the oxidation of fats per liter of oxygen (19.62 1554 
kJ/L). 1555 
 Mean body temperature was calculated as described elsewhere (11).  In short, a 1556 
weighting of 0.8 was assigned to Trec, while 0.2 was assigned to mean Tskin.  This measure was 1557 
calculated to provide an estimate for the central drive for increases in LSR.  While the use of this 1558 
equation can be questionable for estimating changes in heat storage (28), Tbody can be a valuable 1559 
measure for assessing thermosensitivity when applied as the forcing function for increases in 1560 
thermoregulatory sweating.  Thermosensitivity and sweating onset threshold for each subject 1561 
were determined by plotting LSR as a function of increases in Tbody  using segmental linear 1562 
regression analyses (Prism 7, GraphPad Software Inc., La Jolla, CA USA)(10).  Sweating 1563 
thermosensitivity was calculated as the slope of the increase in sweating relative to changes in 1564 
Tbody after sweating onset.  Onset temperature threshold for sweating was calculated as the 1565 
intercept of the thermosensitivity slope with resting sweat rate.  Onset time threshold for 1566 
sweating was calculated in a similar fashion, from the relationship of the increase in sweating 1567 
relative to changes in time.  1568 
Skin blood flow is reported as CVC and calculated by dividing mean LDF values 1569 
(arbitrary units; au) by heart rate-weighted (38) mean arterial pressure (MAP) calculated from 1570 
brachial artery auscultation (3, 31).  CVC data was also normalized to maximal vasodilation 1571 
obtained during the final minute of local heating at 44 °C for 30 min and expressed as percentage 1572 
of maximum CVC (%CVCmax). 1573 
Statistical Analysis 1574 
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 All values are presented as mean ± standard deviation.  Mixed-models ANOVA 1575 
statistical analyses were not performed due to unanticipated differences sample size between 1576 
groups (see Results: Exercise Tolerance).  Therefore, unpaired two-tailed t-tests were utilized to 1577 
compare LSR, WBSL, Tbody, Trec, and Teso at the 30- and 60-minute interval of the exercise 1578 
protocol.  Unpaired t-tests were performed on baseline characteristics and thermal sensitivity.  1579 
All analysis was conducted using IBM SPSS version 23 (IBM, Armonk, NY, USA), and plotted 1580 
via GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA USA).  Statistical significance was 1581 
accepted at p<0.05. 1582 
 1583 
RESULTS 1584 
Subject Characteristics 1585 
Mean subject characteristics are presented in Table 1.  By design, no differences were 1586 
observed in age (p=0.47), body mass (p=0.74), height (p=0.73), and BSA (p=0.71) between MS 1587 
and CON groups.  Disease-modifying treatments used by individuals with MS included the 1588 
following: Avonex (interferon beta-1a), n=2; Gilenya (fingolimod), n=1; Copaxone (glatiramer 1589 
acetate), n=3; Tecfidera (dimethyl fumarate), n=1; Tysabri (natalizumab), n=3; no DMT 1590 
reported, n=2. 1591 
Exercise Tolerance 1592 
The exercise intensity selected for this study was well tolerated in all 12 CON subjects; 1593 
however, only 10 MS subjects were able to complete the entire 60-minute exercise bout.  Two 1594 
MS subjects were unable to complete the exercise protocol and terminated exercise as a result of 1595 
symptom worsening.  One MS subject experienced overwhelming fatigue, while the second MS 1596 
subject lost motor control in one lower limb.  Despite exercise termination, hemodynamic and 1597 
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thermoregulatory responses from both of individuals were similar to those of the rest of the MS 1598 
group.  As such, final exercise values for these two individuals with MS were compared to their 1599 
matched CON at the same time point MS subjects ended exercise (e.g., if MS subject completed 1600 
32 min of exercise, data was compared to values up to minute 32 of exercise of their matched 1601 
CON subject). 1602 
Heat Production 1603 
Heat production during exercise are presented in Table 2.  By design, absolute Hprod (p= 1604 
0.85), Hprod relative to body mass (p=0.40), and Hprod relative to BSA (p=0.41) were all similar 1605 
between groups.  Additionally, external workload (MS: 70 ± 1; CON: 74 ± 7 W, p=0.06) and 1606 
mechanical efficiency (MS: 18.7 ± 3.95; CON: 18.4 ± 1.5%, p=0.85) were similar between 1607 
groups.  1608 
Thermometry 1609 
 Baseline Teso (MS: 37.1 ± 0.4 vs CON: 37.1 ± 0.2 °C, p=0.89) and Trec (MS: 37.2 ± 0.4 vs 1610 
CON: 37.3 ± 0.2 °C, p=0.49) were similar between MS and CON groups.  Core temperature 1611 
responses for both groups during exercise are presented in Figure 1.  The MS group had similar 1612 
(albeit, trending toward significance) Trec compared to CON at both 30 min (n=12v12: p=0.07) 1613 
and 60 min (n=10v10: p=0.19).  Additionally, Teso was similar between groups at the 30- (n=7v7: 1614 
p=0.08) and 60 min (n=5v5: p=0.16) time points. 1615 
 Baseline Tsk was similar between groups (MS: 31.14 ± 0.7 vs CON: 31.63 ± 1.1 °C, 1616 
p=0.15).  Additionally, Tsk was similar at both 30 min (n= 12v12: MS: 31.5 ± 0.8 vs CON: 31.9 1617 
± 0.9 °C, p= 0.19) and 60 min (n= 10v10: MS: 31.8 ± 0.8 vs CON: 31.8 ± 1.2 °C, p=0.85) time 1618 
points.  Therefore, when reported as change from baseline, Tsk was similar at both 30 min 1619 
(p=0.76) and 60 min (p=0.16). 1620 
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 The change in Tbody from baseline was similar at the 30-minute mark (n= 12v12: p=0.09), 1621 
however Tbody rose significantly higher in the MS group compared to CON at 60 min (n= 10v10: 1622 
p=0.02). 1623 
Sweating Responses 1624 
Whole-body sweating responses between groups at the cessation of exercise are 1625 
presented in Figure 2.  WBSL was significantly lower at the 30-minute (p=0.03) as well as the 1626 
60-minute (p=0.02) time points, indicating a blunted cumulative sweating response in MS as 1627 
exercise duration increased.  At 30 min (n=12v12; MS: 0.26 ± 0.17; CON: 0.27 ± 0.15 1628 
mg/cm2/min, p=0.80) as well as the final 1 min (n=12v12; MS: 0.33 ± 0.19; CON: 0.37 ± 0.15 1629 
mg/cm2/min, p=0.69) of exercise, there were no differences in the steady-state ∆LSR between 1630 
groups.  Additionally, total sweat gland recruitment at the 60-minute time point was similar 1631 
between groups (n=10v10; MS: 84.9 ± 51.2; CON: 67.1 ± 29.5, glands/cm2, p=0.38). 1632 
Thermosensitivity & Sweating Onset 1633 
Individual tracings of ∆LSR responses as a function of ∆Tbody during exercise for 1634 
individuals with MS and CON are presented in Figure 3A.  The slope of the relationship between 1635 
∆Tbody and mean ∆LSR (i.e., thermosensitivity) was significantly blunted (p=0.049) in MS 1636 
compared to CON (Figure 3B).  The onset time for sweating was similar between groups (MS: 1637 
10  7 min; CON: 7  4 min, p= 0.31).  In addition to the timing of sweat onset, the threshold 1638 
change in Tbody (n=12v12; MS: 0.16 ± 0.17; CON: 0.05 ± 0.13 °C, p= 0.08) at which a detectable 1639 
increase in sweating occurred was also similar between groups. 1640 
Cutaneous Vasculature Responses 1641 
Skin blood flow responses to exercise are presented in Figure 4.  Baseline LDF 1642 
(n=12v12; MS: 51  14; CON: 61  24 au, p= 0.20), CVC (n=12v12; MS: 0.52  0.14; CON: 1643 
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0.67  0.30 au/mmHg, p= 0.13), and %CVCmax (n=10v10; MS: 18  6; CON: 21  9%, p= 0.26) 1644 
were similar between groups.  Groups had similar increases (change from baseline) in LDF 1645 
(n=10v10: MS: 205  155; CON: 216  69 au, p= 0.81) and CVC (n=10v10; MS: 2.27  1.61; 1646 
CON: 2.53   0.84 au/mmHg, p= 0.63) in response to local heating for ~30 min. 1647 
 1648 
DISCUSSION 1649 
The primary finding of the present study is that individuals with MS had a lower WBSL 1650 
during exercise due to a blunted thermosensitivity (i.e. smaller rise in sweat rate as a function of 1651 
exercise-induced changes in Tbody) compared to CON.  Tbody reached significantly higher levels 1652 
in MS compared to CON during exercise of similar heat production despite no differences in 1653 
internal temperature (Trec and Teso).  In support of our previous findings (3), physiological control 1654 
and function of the cutaneous vasculature is preserved in this clinical population. 1655 
Upon exercise onset, there is a rapid, if not immediate, increase in metabolism to convert 1656 
stored chemical energy into mechanical work.  Since gross mechanical efficiency in humans is 1657 
only ~20% efficient, the net result of this increase in metabolism is an increase in heat 1658 
production, body heat storage, and a rise on core temperature.  As this heat is dispersed 1659 
throughout the body, the body’s core temperature (i.e., tissues and blood) will inevitably rise, 1660 
however the magnitude of this rise is partly dependent on thermoregulatory function.  With intact 1661 
afferent signaling and thermosensory integration, there will be a signal proportional to the rise in 1662 
Tbody out of the CNS to increase in sweat secretion and cutaneous vasodilation, facilitating 1663 
evaporative and dry heat loss from the body, respectively, and thus preventing harmful increases 1664 
in core temperature.  It is this complex autonomic coupling of Tbody and ∆LSR, that appears to be 1665 
dampened by MS, as evidenced by the significantly attenuated relationship between Tbody and 1666 
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LSR (i.e., thermosensitivity, Figure 3).  Similarly, individuals with MS had significantly blunted 1667 
WBSL during the exercise bout relative to CON, despite having to reconcile similar absolute 1668 
heat loads and having a greater drive for sweat production (i.e., Tbody).  While the precise 1669 
mechanisms by which these abnormalities occur remain unclear, clearly a disease disrupting 1670 
conduction within regions of the CNS involved in the thermoregulatory reflex arc would have a 1671 
significant impact on these thermoregulatory processes.  The stripping of myelin sheaths 1672 
surrounding neural axons in the CNS is a hallmark of MS pathophysiology (49, 53).  This 1673 
disruption in signaling can have a slowing (13, 23, 53) and weakening (53) effect on neural 1674 
conduction that could potentially be a contributor in the reduced thermosensitivity and attenuated 1675 
WBSL responses seen in this study.  It is likely this aforementioned demyelination process 1676 
results in increased axonal exposure, thus allowing more current to escape from the axon before 1677 
reaching the axon terminal.  In such case, if the current available in unable to meet the current 1678 
required for signal transmission (i.e., reduced “safety factor”), there may become instances of 1679 
inadequate signaling or even conduction block (49, 53).  Given that individuals with MS were 1680 
able to achieve similar steady-state LSR as CON, it is likely that these neural signaling deficits 1681 
simply result in a weaker sweating response however adequate to permit heat dissipation at 1682 
modest heat loads (environment and/or activity).  The effect of this demyelination is certainly not 1683 
limited to the effector responses observed here, but could also be contributed to: disruptions in 1684 
thermal sensory processing (17), disruptions in processing within the CNS, blunted efferent 1685 
signaling to effector organs through the spinal cord, or some combination therein.  More research 1686 
is warranted to undercover the exact mechanisms responsible for these deficits. 1687 
Although we observed differences in WBSL at multiple time points during exercise in 1688 
this study, measures of LSR did not reach statistical significance at any point.  This is somewhat 1689 
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perplexing given that subjects were matched for absolute metabolic heat production, BSA, and 1690 
therefore relative heat production (W/m2 of BSA).  However, the changes in LSR in this context 1691 
only provide a snapshot of sweat rates at the 30- and 60-minute time points, and perhaps do not 1692 
adequately reflect the cumulative sweating responses that are essential to achieve heat balance.  1693 
Therefore, it is possible these traditional sites for collection of LSR were unaffected by the 1694 
disease.  Similarly, due to the local nature of this measurement, these findings do not rule out 1695 
that there may be impairments at other locations on the body.  Due to the heterogeneities 1696 
associated with MS, perhaps LSR should be obtained at numerous sites in this population going 1697 
forward.   1698 
Interestingly, because of slight differences (statistically non-significant) in Tcore and Tskin 1699 
between groups, individuals with MS had significantly elevated Tbody as a result of exercise.  The 1700 
measure of Tbody it is not without its limitations in scope and accuracy (28).  However, from a 1701 
practical standpoint, using Tbody to assess risk of developing Uhthoff’s phenomenon during 1702 
various activities may be most appropriate for those with MS.  As previously stated, Uhthoff’s 1703 
phenomenon has commonly been reported to develop with a change in Tcore as little as 0.5 °C 1704 
(46).  However, a recent study demonstrated significant increases in postural sway (a common 1705 
symptom of MS) upon acute exposure to warm ambient temperatures in individuals with MS 1706 
(44).  This study revealed acute symptom worsening can occur as a result of increases in Tskin 1707 
alone, independently of changes in Tcore.  Given that estimates of Tbody are aggregates of Tcore and 1708 
Tskin used to estimate mean body temperature, Tbody may be a variable that deserves more 1709 
attention among the MS population.  Clearly more research is warranted on the use of Tbody as an 1710 
indicator of heat stress in the MS population, as well as the role perception may play in eliciting 1711 
acute symptom worsening. 1712 
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Counter to our original hypothesis, changes in Tcore, represented as Teso or Trec, were not 1713 
significantly different between groups in response to the exercise bout selected for this study.  1714 
Therefore, it appears the environment and exercise intensities chosen for this study were well 1715 
within the limits of thermal compensability for subjects in both groups.  This is somewhat 1716 
surprising given the evidence of blunted sweating responses in this study and elsewhere (3, 15, 1717 
41, 47, 59).  As indicated by our data, MS subjects produced similar amounts of heat as CON 1718 
while dissipating less.  This dissociation of heat dissipation and heat production must result in 1719 
elevations in temperature, perhaps in sites that were not directly measured.  While it is beyond 1720 
the scope of this study to speculate exactly where and how this heat is being transferred, perhaps 1721 
the storage of heat in muscle (or other tissues) could play a pivotal role in the onset of Uhthoff’s 1722 
phenomenon and thermal perception in the MS population.  Clearly more research is warranted 1723 
on this issue.   1724 
Supporting previous findings from our lab (3), it appears the cutaneous vasculature in 1725 
persons with MS responds similarly versus CON to an increase in Tcore during exercise in a non-1726 
encapsulated environment. This raises questions regarding how the disease could selectively 1727 
impact sweating responses while the control of the cutaneous vasculature remains intact.  It is 1728 
widely accepted that the primary site of integration of thermoregulatory information is the pre-1729 
optic area of the hypothalamus (6, 7, 37, 51, 52).  There is also growing evidence that this 1730 
information is relayed from the hypothalamus to the medullary raphe regions before activating 1731 
the intermediolateral nucleus of the spinal cord (7, 51, 52).  Upon leaving the spinal cord, signals 1732 
branch along nerves in the peripheral nervous system, ultimately arriving at the thermoregulatory 1733 
end-organs.  While the aforementioned pathway is the culmination of many studies and detailed 1734 
analysis, the majority of this work has been conducted in rats or other species rather than 1735 
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humans.  With this in mind, perhaps lesions as a result of MS are more prevalent in CNS 1736 
pathways for sweating, and these pathways are yet to be elucidated.  As an alternative 1737 
explanation, it is possible the exercise intensities chosen were not demanding enough to elicit 1738 
discernable differences in the CVC responses to exercise.  However, as previously mentioned, 1739 
the intensities selected in the current study were chosen to elicit the greatest change in Tcore while 1740 
remaining low enough that this clinical population could complete the trials.  Therefore, given 1741 
that moderate environmental conditions (25°C) were employed in the present study, future 1742 
research should urgently examine potential thermoregulatory impairments with MS under 1743 
warmer conditions.  This research would be particularly relevant to clinical reports of Uhthoff’s 1744 
phenomenon, which dramatically peak in the warmer summer months of the year. 1745 
Limitations 1746 
 Although our findings are consistent with CNS impairments (1, 19, 38, 51), it remains 1747 
possible that our results were influenced by DMT prescribed to individuals with MS.  Patients 1748 
were carefully screened for additional medications (i.e., anti-depressants, psychostimulants, anti-1749 
convulsants, anti-spasmatics, and anti-cholinergics), and precautions were taken to remove any 1750 
clear outliers that may influence group data.  With this in mind, immediate prescription of DMT 1751 
upon diagnosis is the current standard of care (9), thus a critical understanding of individuals 1752 
with MS currently on these medications is warranted. 1753 
The exercise intensity chosen was both of low intensity for CON individuals while being 1754 
quite challenging for some individuals with MS (2 of 12 individuals had to stop the exercise trial 1755 
~30 min early).  Due to the conservative workload chosen, any differences might be more 1756 
apparent and robust with higher workloads/heat loads.  However, it is important to examine heat 1757 
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loss responses at ecologically valid intensities in which the majority of the MS population is 1758 
capable of performing in their daily lives. 1759 
As mentioned previously, LSR and LDF/CVC values were collected over small skin 1760 
areas (<3 cm2).  While this was the consistent across all subjects (i.e., CON & MS), it is unclear 1761 
how the lesions caused by MS could affect the efferent signal going to these specific sites, for 1762 
each person.  With a clinical condition that elicits seemingly random lesions throughout the 1763 
CNS, no two people are affected in the same magnitude and/or locations of lesions, and therefore 1764 
our measurements could be biased by the local nature of these measurements.  However, as 1765 
shown in Figures 3 & 4, our localized measurements of LSR and CVC are similar between MS 1766 
and CON, therefore we may not be capturing the dysfunction in areas not being measured.  If 1767 
this is the case, this would add to the severity of thermoregulatory dysfunction among 1768 
individuals with MS observed in this study.  1769 
Clinical Significance 1770 
Based on these results, individuals with MS could face a substantial obstacle when it 1771 
comes to maintaining an active lifestyle.  While there is much evidence in support of the benefits 1772 
of exercise in this population (25, 26, 42, 43), it appears even exercise intensities that generate 1773 
modest amounts of heat are capable of eliciting exaggerated increases in Tbody, as well as the 1774 
rapid onset of Uhthoff’s phenomenon in some.  This is practically significant because 40-80% of 1775 
the MS population (16, 19, 21, 22) can experience this acute worsening of their symptoms as a 1776 
result in modest elevations in Tcore (46) or Tsk (44).  Therefore, while the benefits of exercise in 1777 
the MS population remain absolutely undisputed, the obtainment of these beneficial adaptations 1778 
may come at a risk for those seeking to live an active lifestyle, especially as their disease course 1779 
progresses or as warm summer months approach.  Based on these findings, it is imperative that 1780 
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individuals with MS are aware of these thermoregulatory limitations and have a ready and 1781 
accessible cooling strategy in place prior to engaging in even modest exercise intensities.  1782 
Additionally, while promising studies have determined that exercise tolerance can be improved 1783 
with cooling strategies (9) in MS, more research is warranted to identify the most impactful 1784 
means to accomplish these goals. 1785 
Conclusion 1786 
 Individuals with MS are at a greater risk for thermoregulatory dysfunction and thus more 1787 
vulnerable to exaggerated elevations in body temperature (internal and/or skin) than disease free 1788 
individuals.  While our results indicate that individuals with MS are able to achieve a steady-1789 
state Tcore and LSR in the exercise intensity and environmental conditions chosen for this study, 1790 
WBSL values as well as sweating thermosensitivity were significantly blunted in those with MS 1791 
compared to CON.  Taken together, it appears individuals with MS can achieve a thermal steady-1792 
state to exercise intensities of a modest heat load, however there is evidence that this ability may 1793 
reach its capacity before the healthy population.  Given the prevalence of Uhthoff’s phenomenon 1794 
among this population, it is imperative that more research is done to define the limits of 1795 
compensability in this population, as well as identify ways to mitigate the risks of excessive 1796 
heating during physical activity in MS. 1797 
  1798 
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Table 1.  Subject characteristics. 1969 
 MS (n=12) CON (n=12) p-value 
Age (y) 40 ± 9 36 ± 13 0.47 
Weight (kg) 78 ± 14 76 ± 18 0.73 
Height (cm) 175 ± 11 173 ± 10 0.74 
BSA (m2) 1.9 ± 0.2 1.9 ± 0.3 0.71 
Heart rate (bpm) 76 ± 17 73 ± 10 0.52 
Systolic blood pressure (mmHg) 126 ± 25 116 ± 10 0.08 
Diastolic blood pressure (mmHg) 80 ± 10 81 ± 10 0.90 
Mean arterial blood pressure (mmHg) 96 ± 10 93 ± 9 0.43 
 1970 
BSA, body surface area. 1971 
  1972 
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Table 2.  Heat production during exercise. 1973 
 MS (n=12) CON (n=12) p-value 
Absolute Heat Production (W) 314 ± 65 309 ± 49 0.85 
Heat Production per unit mass (W/kg) 4.2 ± 0.7 4.5 ± 1.1 0.40 
Heat Production per unit BSA (W/m2) 162 ± 22 170 ± 25 0.41 
 1974 





Figure 1.  Mean changes in esophageal (Teso; panel A) and rectal (Trec; panel B) temperature 1979 
from resting baseline (±SD) at 30 min and 60 min of exercise at a fixed rate of heat production in 1980 
persons with multiple sclerosis (MS) and healthy controls (CON). 1981 
 1982 
 1983 
Figure 2.  Mean changes in whole-body sweat loss (WBSR; panel B) from resting baseline 1984 
(±SD) at 30 min and 60 min of exercise at a fixed rate of heat production in persons with 1985 
multiple sclerosis (MS) and healthy controls (CON).  *Significantly different than CON. 1986 
 1987 
 1988 
Figure 3.  Representative tracing of changes in local sweat rate (LSR) expressed relative to the 1989 
change in mean body temperature (Tbody) from one individual with MS and a matched CON 1990 
subject (panel A); and mean slope (±SD) of the LSR-Tbody relationship (i.e., thermosensitivity; 1991 
panel B) during exercise at a fixed rate of heat production in persons with multiple sclerosis 1992 
(MS) and healthy controls (CON).  *Significantly different than CON. 1993 
 1994 
 1995 
Figure 4.  Mean changes in laser-Doppler flux (LDF; panel A), mean change in absolute 1996 
cutaneous vascular conductance (au/mmHg; panel B) and mean change in cutaneous vascular 1997 
conductance expressed as percent of maximal vasodilation to local heating (%CVCmax; panel C) 1998 
from baseline (±SD) during exercise at a fixed rate of heat production in persons with multiple 1999 
sclerosis (MS) and healthy controls (CON). 2000 
 2001 
 2002 
  2003 
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Figure 1. 2004 
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CHAPTER 4 2023 
 2024 
 2025 
Does MS cause peripheral impairments in sweat rate and skin blood flow compared to 2026 




Chapters 2 and 3 provide evidence of thermoregulatory reflex impairments in sweat rate as a 2031 
result of MS.  While it would be feasible to assume that these impairments in sweating are due to 2032 
disruptions in neural conduction that accompany MS, it remains possible that there are 2033 
maladaptations in peripheral end-organs (e.g., sweat glands and cutaneous vasculature) as a 2034 
result of the disease.  Therefore, the following study used intradermal microdialysis drug 2035 
infusions to stimulate sweat glands and cutaneous vasodilation to assess peripheral 2036 
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ABSTRACT 2076 
Impaired autonomic control of the thermoregulatory system has been reported in multiple 2077 
sclerosis (MS).  It is unclear whether blunted thermoregulatory responses are of central origin or 2078 
attributed to peripheral impairment of thermoregulatory effectors secondary to the disease.  This 2079 
study tested the hypothesis that post-synaptic sweating would be attenuated in individuals with 2080 
MS compared to healthy controls, while cutaneous vasodilatory responses would be similar.  2081 
Nine individuals with relapsing-remitting MS (6 females, 3 males) and 9 matched healthy 2082 
controls participated.  Four microdialysis probes with semipermeable membranes were placed in 2083 
the dermal layer of dorsal forearm skin allowing delivery of increasing log-molar doses of 2084 
methacholine (MCh; 1 x 10-7 to 1 M) or sodium nitroprusside (SNP; 5 x 10-8 to 5 x 10-2 M).  2085 
Sweat rate (SR) and skin blood flow (laser-Doppler flux: LDF) were continuously measured over 2086 
two probes receiving MCh and LDF only over two probes receiving SNP.  Cutaneous vascular 2087 
conductance (CVC) was calculated (ratio of LDF to mean arterial pressure) and expressed as 2088 
percentage of maximum achieved during 50mM SNP perfusion following log molar dosing.  SR 2089 
(p=0.64) and endothelial-dependent increases in %CVCmax (p=0.83) to MCh were similar 2090 
between groups.  Endothelial-independent increases in %CVCmax to SNP were similar (p=0.95) 2091 
between groups.  Post-synaptic cutaneous vasculature responsiveness (drug concentration 2092 
evoking 50% response; EC50) were similar between groups for both drugs (p>0.05).  Peripheral 2093 
thermoregulatory end-organ function remains intact in MS suggesting reductions in sweating are 2094 
of central rather than peripheral origin.  The cutaneous vasculature is unaffected by MS 2095 
regardless of central or peripheral stimuli. 2096 
  2097 
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NEW AND NOTEWORTHY 2098 
While accumulating evidence demonstrates abnormal thermoregulatory responses as a result of 2099 
multiple sclerosis, this study is the first to assess whether this disease leads to peripheral 2100 
thermoregulatory end-organ impairment.  The findings from this study provide mechanistic 2101 
information that peripheral responsiveness of the cutaneous vasculature and sweat glands is 2102 
preserved in MS.  This suggests the documented reductions in sweating in individuals with MS is 2103 
of central- rather than peripheral origin. 2104 
  2105 
 103 
INTRODUCTION 2106 
Multiple sclerosis (MS) is an autoimmune disease that causes lesions within the brain and 2107 
spinal cord affecting ~2.5 million people worldwide (10, 48).  While the exact cause of this 2108 
disease remains unknown, abnormal activation of B and T lymphocytes have been implicated in 2109 
the destruction of myelin and healthy neurons within the central nervous system (CNS) (13).  2110 
This deterioration of the insulating properties of myelin results in neural signal disruption (36), 2111 
ultimately leading to a complex array of clinical signs and symptoms (5, 19, 46, 50).  2112 
Compounding these problems, individuals with MS experience symptom augmentation during 2113 
elevations in body temperature known as Uhthoff’s phenomenon (16, 49).  Uhthoff’s 2114 
phenomenon is acute, not leading to symptom progression, but greatly impacts quality of life (6, 2115 
13, 22).  Therefore, these individuals are extremely heat-sensitive and must take extra precaution 2116 
when faced with a thermoregulatory challenge (elevated ambient temperatures, physical activity, 2117 
or both) (8, 20). 2118 
Elevations in body temperature lead to Uhthoff’s phenomenon.  Therefore, it is 2119 
imperative individuals with MS have highly functional heat dissipation mechanisms.  Blunted 2120 
thermoregulatory reflex sweating as a function of elevations in body temperature during whole-2121 
body passive heating have been observed in person with MS (1).  Furthermore, it was observed 2122 
that blunted sweating during physical activity, lead to exaggerated increases in body temperature 2123 
(Tbody) and onset of Uhthoff’s phenomenon in heat-sensitive individuals with MS (Allen et al., in 2124 
review).  Taken together, it appears individuals with MS have thermoregulatory dysfunction 2125 
associated with increasing output from sweat glands.  This dysfunction when faced with a 2126 
hyperthermic challenge, limits the ability defend against rises in body temperature, and therefore, 2127 
the onset of Uhthoff’s phenomenon. 2128 
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Abnormal sweating responses in MS could be of central origin, peripheral origin, or a 2129 
combination.  Although MS is a disease primarily affecting the CNS, blunted sweating responses 2130 
reported in our lab (1) and elsewhere (39, 41, 50) could potentially be attributed to peripheral 2131 
impairment of thermoregulatory effectors (sweat glands and skin blood vessels) due to decreased 2132 
muscarinic receptor sensitivity or responsiveness, sweat gland atrophy, or other maladaptations 2133 
occurring in this clinical population. 2134 
Intradermal microdialysis allows for the investigation of post-synaptic sensitivity and 2135 
responsiveness of sweat glands and the cutaneous vascular via infusion of sudomotor and 2136 
vasomotor agonists. Because end-organs are activated directly, this methodology is not impacted 2137 
by central MS maladaptations and independent of increases in core temperature (i.e. ambient 2138 
heat exposure and/or physical activity).  In addition, pharmacological approaches can be utilized 2139 
with intradermal microdialysis via the infusion of methacholine (MCh; acetylcholine agonist) to 2140 
determine dose-dependent responses in sweating and endothelial-dependent cutaneous 2141 
vasodilation while infusion of sodium nitroprusside (SNP, a nitric oxide donor) to determine 2142 
dose-dependent responses in endothelial-independent cutaneous vasodilation.  Therefore, the 2143 
purpose of this study was to test the hypothesis that post-synaptic sweating responses would be 2144 
attenuated individuals with MS while endothelial-dependent and independent cutaneous 2145 




Individuals with definite relapsing-remitting MS [MS, n=9 (6 females, 3 males), 2150 
expanded disability status scale, EDSS:  range 0-6] and age-, sex-, height-, and weight-matched 2151 
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healthy controls [CON, n=9) (6 females, 3 males)] voluntarily participated in this study.  Based 2152 
upon differences in sweating between individuals with MS and healthy controls from a previous 2153 
study (1), an effect size of 1.26 was calculated.  A power calculation (  = 0.05, power = 0.80) 2154 
revealed a minimum sample size of 18 subjects (9 MS, 9 CON) were needed for the current 2155 
study (G*power software, version 3.1.9.3). 2156 
All individuals with MS were otherwise healthy, but clinically diagnosed with MS and 2157 
currently being treated by neurologists specializing in MS at the MS Clinic at the University of 2158 
Texas Southwestern Medical Center.  This study focused on relapsing-remitting MS because it is 2159 
the most common disease course with ~85% of individuals with MS initially diagnosed with this 2160 
form of the disease (54).  This form of MS is characterized by acute attacks (exacerbations) 2161 
followed by periods of partial or complete recovery (remissions) (54).  All individuals with MS 2162 
were on disease-modifying therapies.  According to the 2015 consensus paper by the Multiple 2163 
Sclerosis Coalition, FDA-approved disease-modifying treatment (DMT) is recommended and 2164 
should be continued indefinitely (9).  Individuals with MS on symptom modifying therapies that 2165 
are known to affect the CNS and/or thermoregulatory responses (i.e., anti-depressants, 2166 
psychostimulants, anti-convulsants, anti-spasmatics, and anti-cholinergics) were excluded from 2167 
the study.  Individuals with MS remained on their DMT as prescribed by their neurologists but 2168 
were asked to refrain from taking any additional supplements and/or over-the-counter 2169 
medications prior to testing.  All individuals with MS were tested during a stable phase of their 2170 
disease and were at least 6 months removed from their most recent relapse. 2171 
All subjects were non-smokers and had no history of metabolic, pulmonary, or 2172 
cardiovascular disease.  Subjects refrained from caffeine, alcohol, and vigorous exercise 24 h 2173 
prior to the trial.  All trials took place between 07:00-11:00 a.m. to avoid potential effects of 2174 
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circadian rhythm and outside of summer months in an effort to avoid any differences associated 2175 
with acclimation status or heat storage prior to beginning the protocols.  All procedures were 2176 
approved by the Institutional Review Boards at Southern Methodist University (Dallas, TX, 2177 
USA) and the University of Texas Southwestern Medical Center (Dallas, TX, USA), and all 2178 
conformed to the Declaration of Helsinki.  All subjects were instructed on the protocol and 2179 
provided their written informed consent prior to participation in the study. 2180 
Instrumentation 2181 
Following the completion of a medical history and consent documents, subjects rested in 2182 
a ~24°C laboratory in the semi-recumbent position (~45° angle) during the placement of four 2183 
microdialysis probes in the dorsal forearm: 2 proximal, 2 distal.  Each probe was placed ≥ 3 cm 2184 
apart to allow space between each 10 mm membrane window.  A 25-gauge needle was utilized 2185 
to pierce the dermal space and exited ~20 mm from the entry point.  Each microdialysis probe 2186 
was inserted through the lumen of the needle.  Each microdialysis membrane consisted of two 2187 
reinforced sections of polyimide tubing connected to a 1-cm dialysis membrane (Bio-analytical 2188 
Systems, West Lafayette, IN).  As the needle was removed, the 10 mm semipermeable dialysis 2189 
membrane window was centered in the dermal layer at an estimated depth of 0.3-1.0 mm.  2190 
Following successful probe placement, lactated Ringer solution was perfused through all 2191 
membranes at 2 µl/min via an infusion pump (Pump 11, Havard Apparatus, Natick, MA).  Two 2192 
microdialysis probe sites (one proximal and one distal) were instrumented with custom built 2193 
capsules attached to the skin directly above each microdialysis membrane using adhesive tape 2194 
(3M, Saint Paul, MN).  Local sweat rate (LSR) was measured via capacitance hygrometry 2195 
(Vaisala, Woburn, WA, USA) with the capsules perfused with 100% nitrogen at a flow rate of 2196 
300 ml/min.  Each capsule also housed a laser Doppler flowmetry probe (Perimed model PF 413) 2197 
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allowing simultaneous measurement of laser Doppler flux (LDF) over each microdialysis 2198 
membrane.  Two sites were perfused with MCh, SR and LDF were collected concurrently using 2199 
LDF probes housed within the custom built sweat capsules.  The two remaining microdilaysis 2200 
probe sites (one proximal and one distal), only laser Doppler flowmetry probes were attached to 2201 
the skin directly above each microdialysis membrane via a plastic probe holder with adhesive 2202 
tape.  Brachial artery blood pressure was obtained in the opposite arm via auscultation (SunTech 2203 
Medical Instruments, Raleigh, NC). 2204 
Protocol 2205 
Following microdialysis probe placement and instrumentation, each site was perfused 2206 
with lactated Ringer solution for 90 min while the hyperemic response from needle trauma 2207 
subsided.  After the hyperemic period, baseline LSR, LDF, and MAP data was collected for 5 2208 
min.  Following baseline, the two microdialysis probes instrumented with sweat capsules and 2209 
laser Doppler flowmetry probes were perfused with increasing doses of MCh (1 x 10-7 M to 1 M; 2210 
8 log-molar increments) dissolved in Ringer solution.  MCh (Sigma-Aldrich, MO, USA) is a 2211 
non-selective muscarinic receptor agonist and analog of acetylcholine released from sympathetic 2212 
cholinergic nerves.  Stimulation of muscarinic receptors on eccrine sweat glands induces 2213 
sweating and on endothelial cells induces endothelial-dependent cutaneous vasodilation.  MCh 2214 
was selected due to its acetylcholinesterase resistance and muscarinic receptor end-organ 2215 
potency (32).  The remaining 2 membranes were perfused with increasing doses of SNP (5 x 10-8 2216 
to 5 x 10-2 M; 7 log-molar doses).  SNP (Nitropress®, Valeant, Rochester, NY) is a nitric oxide 2217 
donor which stimulates the cGMP pathway of vascular smooth muscle causing relaxation.  Each 2218 
drug dose began with a 1 min washout period at 102 µl/min, followed by 5-min perfusion at 2 2219 
µl/min.  Following the final dose of the respective drug, 5 x 10-2 M SNP was administered for 2220 
 108 
~20 min to elicit maximal vasodilation at each probe site previously receiving doses of MCh (27, 2221 
28). 2222 
Data Analysis 2223 
Data were continuously obtained and digitized at a sampling rate of 200 Hz (Biopac 2224 
System, Santa Barbara, CA).  The final 30 s interval of each dose of MCh and SNP was selected 2225 
for analysis for each microdialysis probe.  To control for the heterogeneity of responses, 2226 
measurements at both proximal and distal sites of each drug for LDF/CVC and SR were 2227 
averaged together for each subject.  For maximal vasodilation (i.e., 5 x 10-2 M SNP), the final 60 2228 
s were selected for analysis and both proximal and distal sites for each drug were averaged 2229 
together in the same manner.  MAP was calculated utilizing a heart rate weighted formula (1, 33, 2230 
37).  Cutaneous vascular conductance (CVC) was calculated as the ratio of LDF to MAP.  CVC 2231 
was normalized relative to each site’s maximal CVC and expressed as %CVCmax.  Dose-response 2232 
curves for CVC at each of the four sites for each subject were constructed using a nonlinear 2233 
fitting technique with a Hill slope of 1.0 using GraphPad Prism 7 (GraphPad Software Inc., La 2234 
Jolla, CA USA) (11).  From each dose-response relationship, the effective concentration that 2235 
elicits a 50% maximal response (EC50) at each of the four sites was calculated for each subject 2236 
and used as a measure of post-synaptic responsiveness.  EC50 values for proximal and distal sites 2237 
for each drug were averaged together for each subject.  Mathematical modeling was unable to 2238 
generate sweating dose response curves due to non-sigmoidal sweating responses to MCh. 2239 
Statistical Analysis 2240 
All values are presented as mean ± standard deviation.  Post-synaptic SR responses were 2241 
analyzed using a two-way repeated measures ANOVA (main effects: group x drug dose)  2242 
Endothelial-dependent and endothelial-independent CVC responses to MCh and SNP, 2243 
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respectively, were analyzed using a repeated measures two-way ANOVA (main effects: group x 2244 
drug dose ).  Mean EC50 values for each drug were compared between groups using independent 2245 
t-tests.  All analysis was conducted using IBM SPSS version 23 (IBM, Armonk, NY, USA), and 2246 
plotted via GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA USA).  Statistical 2247 
significance was accepted at p<0.05. 2248 
 2249 
RESULTS 2250 
Subject Characteristics 2251 
Subject characteristics for MS and CON are presented in Table 1.  By design, age 2252 
(p=0.31), height (p=0.97), and body mass (p=0.53) were similar between groups.  Disease-2253 
modifying treatments used by individuals with MS included the following: Avonex (interferon 2254 
beta-1a), n=4; Copaxone (glatiramer acetate), n=2; Tysabri (natalizumab), n=3. 2255 
Hemodynamic Responses 2256 
Baseline systolic (MS: 110 ± 6; CON: 111 ± 8 mmHg, p=0.84), diastolic (MS: 70 ± 5; 2257 
CON: 69 ± 9 mmHg, p=0.12), and mean arterial (MS: 83 ± 5; CON: 83 ± 8 mmHg, p=0.27) 2258 
mean arterial blood pressure were similar between MS and CON.  Throughout the experimental 2259 
drug dosing protocol, blood pressure remained similar between the groups (group effect: p=0.73; 2260 
dose effect: p=0.99; interaction: p=0.50). 2261 
Sweating Responses to MCh Infusion 2262 
 Transepithelial water loss at baseline was trending but did not reach statistical 2263 
significance between groups (MS: 0.29 ± 0.15; CON: 0.15 ± 0.15 mg/cm2/min, p=0.06).  2264 
Methacholine-induced increases in sweat rate were similar between groups (Figure 1). 2265 
Cutaneous Vasculature Responses to MCh and SNP Infusions 2266 
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Baseline LDF (MS: 30 ± 9; CON: 30 ± 11 au, p=0.88), CVC (MS: 0.37 ± 0.11; CON: 2267 
0.36 ± 0.13 au/mmHg, p=0.82), and %CVCmax (MS: 16 ± 6; CON: 15 ±7 %, p=0.69) were 2268 
similar between groups at SNP sites.  At MCh sites, baseline LDF (MS: 16 ± 11; CON: 32 ± 14 2269 
au, p=0.02) and CVC (MS: 0.19 ± 0.12; CON: 0.39 ± 0.18 au/mmHg, p=0.01) were significantly 2270 
different between groups.  When expressed as a %CVCmax (MS: 10 ± 7; CON: 17 ±8 %, p=0.06), 2271 
group differences were no longer apparent. 2272 
Dose-response changes in %CVCmax from baseline were similar for MCh (Figure 2A) 2273 
and SNP (Figure 3A) between groups.  Additionally, the log-molar dosage of MCh (Figure 2B) 2274 
and SNP (Figure 3B) necessary to elicit the EC50 cutaneous vascular responses were similar 2275 
between groups.  2276 
Maximal LDF and CVC responses to a ~20 min maximal dose of SNP was similar 2277 
between MS and CON at both the MCh (LDF, MS: 163 ± 44; CON: 193 ± 66 au, p=0.27 & 2278 
CVC, MS: 1.96 ± 0.49; CON: 2.41 ± 0.83 au/mmHg, p=0.19) and SNP (LDF, MS: 189 ± 51; 2279 
CON: 201 ± 46 au, p=0.61; CVC, MS: 2.37 ± 0.68; CON: 2.48 ± 0.60 au/mmHg, p=0.73) sites. 2280 
 2281 
DISCUSSION 2282 
 The primary findings of the current study indicate that intradermal administration of MCh 2283 
and SNP via microdialysis demonstrated no peripheral post-synaptic thermoregulatory end-organ 2284 
impairments in MS.  Counter to our initial hypothesis, post-synaptic sweating responses were 2285 
similar between MS and CON in response to infusion of MCh.  Additionally, it appears both 2286 
endothelial-dependent (infusion of MCh) as well as endothelial-independent (infusion of SNP) 2287 
cutaneous vasodilation were similar between persons with MS and healthy controls.  The current 2288 
 111 
findings suggest that deficits in sweating previously reported in MS (1, 39, 41, 42, 50) are likely 2289 
of central origin rather than peripheral maladaptations secondary to the disease process. 2290 
 Our initial hypothesis of peripheral maladaptations in the sudomotor pathway and/or 2291 
eccrine glandular changes are reasonable expectations given previous data using single-dose 2292 
pilocarpine iontophoresis (13) and knowledge of disease etiology which includes central nervous 2293 
system impairments causing conduction abnormalities and even neuronal loss within the 2294 
descending sudomotor system (1, 27).  Insufficient sympathetic input to sweat glands could lead 2295 
to peripheral adaptations including glandular atrophy, reductions in sweat gland nerve fiber 2296 
density, and reduced cholinergic sensitivity and/or responsiveness via downregulation of 2297 
muscarinic receptors or their associated second messenger pathways.  Conditions that result in 2298 
chronic increases or decrease in skin sympathetic nerve activity have observed glandular 2299 
atrophy, hypertrophy, among other descriptive changes (43, 44).  Alternations in sweat gland coil 2300 
size and basolateral in folding can affect the overall ion and water transport and thus affecting 2301 
maximal sweat rates per gland.  No changes in maximal sweat rate were observed between 2302 
individuals with MS and controls indicating that gland size and basolateral in folding appear to a 2303 
less likely mechanism of impaired sweat function. Cutaneous sensory deficits have been 2304 
observed in individuals with MS (15), these deficits can indicate peripheral neuropathy which is 2305 
often associated with decreases in sweat gland nerve fiber density (18).  The current study did 2306 
not observe post-synaptic impairments in sweating when stimulated by MCh administration.  2307 
Thus, it is also unlikely that sweat gland nerve fiber density is a predominant factor in the 2308 
sweating impairment observed in MS.  Cholinergic sensitivity, assessed by EC50, can be altered 2309 
with adaptions to chronic skin sympathetic nerve activity induced by bedrest and physical 2310 
activity (12).  The current data did not reveal rightward shifts in the EC50 or decreases in Emax, 2311 
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indicating that in vivo cholinergic sensitivity and responsiveness were not altered.  Combined, 2312 
these data indicate that eccrine glands, local sudomotor nerves, and receptors and associated 2313 
pathways are largely unaltered by MS. 2314 
A previous study examining post-synaptic sweat function utilizing single-dose 2315 
pilocarpine iontophoresis to maximally stimulate sweat glands in individuals with MS indicated 2316 
reduced sweat rates as well as sweat gland output per gland (14).  These single-point pilocarpine 2317 
iontophoresis results differ from the current intradermal microdialysis dose-responses. 2318 
Differences between studies could be attributed to methodological distinctions.  Iontophoresis 2319 
utilizes an electrical current for transdermal drug delivery and currents per se can alter the local 2320 
cutaneous internal milieu via altering blood flow, paracrine signaling, and stimulate sensory 2321 
afferents (34, 47).  The pilocarpine protocol involves a single-dose (1-2 cycles of 5.5 min at 1.5 2322 
mA current delivered through 0.5% pilocarpine nitrate in solid agar gel), rather than stepwise 2323 
agonist doses and thereby prevents the assessment of dose-response relationships.  Besides 2324 
dosing limitations, pilocarpine iontophoresis technique may not be reflective of exercise sweat 2325 
rates or submaximal sweat rates (9) and has considerable variability associated with the measure 2326 
(3, 23, 31).  Thus, sweat measurements using the microdilalysis technique may be more 2327 
reflective of physiological sweating and combined with the ability to perfuse multiple-doses 2328 
appears to improve confidence in the biological responses. 2329 
 Using the technique of intradermal injections of MCh to activate endothelial cells is a 2330 
powerful tool to investigate endothelial-dependent vasodilation thus smooth muscle relaxation 2331 
(i.e., vasodilation).  MCh binds to muscarinic receptors on endothelial cells, triggering a 2332 
pronounced vasodilatory cascade (17).  Joint activation of: 1) prostaglandins (24, 29, 30), 2) NO 2333 
synthase, combining with L-arginine resulting in NO release at the smooth muscle (25, 27, 29), 2334 
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3) vasoactive intestinal peptide (VIP) as a co-transmitter (4), and 4) other non-NO and non-2335 
prostanoid-dependent mechanisms (24) causing smooth muscle relaxation and ultimately, 2336 
vasodilation.  In the current study, there were no differences in MCh-induced vasodilation at any 2337 
drug concentration between individuals with MS and healthy controls suggesting no endothelial 2338 
dysfunction at the cutaneous vasculature as a result of MS. 2339 
No differences between individuals with MS and healthy controls were observed in 2340 
cutaneous vascular responses when log-molar doses of the no donor, SNP, was administered 2341 
indicating smooth muscle surrounding cutaneous vessels was equally as responsive to NO in 2342 
individuals with MS as matched healthy controls.  Taken together, post-synaptic responsiveness 2343 
of the cutaneous vasculature including endothelial dependent and endothelial independent 2344 
mechanisms, is unaffected by MS supporting previous findings (1). 2345 
 From our previous work (1, 26) and that of others (2, 9, 39), there is clearly dysfunction 2346 
in the autonomic nervous system caused by MS-induced disruptions in the CNS leading to 2347 
impairments in thermoregulatory function.  Brain and spinal cord MS lesions, while seemingly 2348 
random in time and space (7, 21, 38), are more concentrated in certain CNS areas such as the 2349 
hypothalamus (40).  Demyelination within the hypothalamus that leads to slowing or weakened 2350 
neural signaling, or possibly conduction block (35, 36, 45) could result in reductions in 2351 
thermoregulatory sweating (1, 39, 41, 42, 50).  This may explain deficits in sweating when 2352 
stimulated centrally, such as during passive heating where individuals with MS were capable of 2353 
generating only ~70% of the sweat rate of healthy control counterparts (1).  While this may lead 2354 
to increases in internal temperature and Uhthoff’s phenomenon, there is still a sympathetic signal 2355 
being sent to cutaneous thermoregulatory end-organs.  Thus, this dampened signal to the sweat 2356 
gland is likely not sufficient to cause chronic maladaptations resulting in sweat gland atrophy, 2357 
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decreased sweat gland nerve fiber density, or decreased in vivo muscarinic receptor sensitivity 2358 
and responsiveness.  Further research is warranted to investigate whether these adaptations occur 2359 
in a more severe, progressive forms of this disease. 2360 
Limitations 2361 
 Although our findings are consistent with CNS impairments (1, 19, 38, 51), it remains 2362 
possible that our results were influenced by DMT prescribed to individuals with MS.  Patients 2363 
were carefully screened for additional medications (i.e., anti-depressants, psychostimulants, anti-2364 
convulsants, anti-spasmatics, and anti-cholinergics), and precautions were taken to remove any 2365 
clear outliers that may influence group data.  With this in mind, immediate prescription of DMT 2366 
upon diagnosis is the current standard of care (9), thus improving our understanding of 2367 
individuals with MS currently on these medications warranted. 2368 
Conclusion 2369 
 Taken together, the results of the current study demonstrate peripheral thermoregulatory 2370 
end-organ function remains intact in individuals with MS compared to healthy controls.  This 2371 
study provides support for the theory that reductions in thermoregulatory sweating in relapsing-2372 
remitting MS are of central-, rather than peripheral origin.  Additionally, these findings also 2373 
support that control and function of the cutaneous vasculature is seemingly unaffected by MS, 2374 
regardless of the location of the stimuli (i.e., central or peripheral).  Further research is warranted 2375 
to better isolate the exact location and cause of abnormal sweating responses seen in this 2376 
population, however these results indicate that peripheral impairments due to maladaptations are 2377 
not a likely mechanism. 2378 
 2379 
Acknowledgments 2380 
 The considerable time and effort of the subjects are greatly appreciated. 2381 
 2382 
Grants 2383 
 This study was supported by National Heart, Lung, and Blood Institute grant R15-HL-2384 
117224 (S. L. Davis) and National Multiple Sclerosis Society grants RG4043A1/1 and 2385 
RG4696A3/2 (S. L. Davis) 2386 
 2387 
Disclosures 2388 
 No conflicts of interest, financial or otherwise, are declared by the authors. 2389 
  2390 
 116 
REFERENCES 2391 
1.  Allen DR, Huang M, Parupia IM, Dubelko AR, Frohman EM, Davis SL. Impaired 2392 
sweating responses to a passive whole body heat stress in individuals with multiple 2393 
sclerosis. J Neurophysiol 118: 7–14, 2017. 2394 
2.  Andersen EB, Nordenbo AM. Sympathetic vasoconstrictor responses in multiple sclerosis 2395 
with thermoregulatory dysfunction. Clin Auton Res 7: 13–16, 1997. 2396 
3.  Åsberg A, Holm T, Vassbotn T, Andreassen AK, Hartmann A. Nonspecific 2397 
microvascular vasodilation during iontophoresis is attenuated by application of 2398 
hyperosmolar saline. Microvasc Res 58: 41–48, 1999. 2399 
4.  Bennett Lee Ann T., Johnson John M., Stephens Dan P., Saad Adham R., Kellogg 2400 
Dean L. Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the 2401 
cutaneous vasculature of humans. J Physiol 552: 223–232, 2004. 2402 
5.  Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of 2403 
bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56: 245–250, 2404 
1993. 2405 
6.  Bol Y, Smolders J, Duits A, Lange IMJ, Romberg-Camps M, Hupperts R. Fatigue and 2406 
heat sensitivity in patients with multiple sclerosis. Acta Neurol Scand 126: 384–389, 2012. 2407 
7.  Calabrese M, Battaglini M, Giorgio A, Atzori M, Bernardi V, Mattisi I, Gallo P, De 2408 
Stefano N. Imaging distribution and frequency of cortical lesions in patients with multiple 2409 
sclerosis. Neurology 75: 1234–1240, 2010. 2410 
8.  Capello E, Gardella M, Leandri M, Abbruzzese G, Minatel C, Tartaglione A, 2411 
Battaglia M, Mancardi GL. Lowering body temperature with a cooling suit as 2412 
symptomatic treatment for thermosensitive multiple sclerosis patients. Ital J Neurol Sci 16: 2413 
533–539, 1995. 2414 
9.  Cartlidge NEF. Autonomic function in multiple sclerosis. Brain 95: 661–664, 1972. 2415 
10.  Compston A, Coles A. Multiple sclerosis. The Lancet 359: 1221–1231, 2002. 2416 
11.  Crandall CG, Davis SL. Cutaneous vascular and sudomotor responses in human skin 2417 
grafts. J Appl Physiol 109: 1524–1530, 2010. 2418 
12.  Crandall CG, Shibasaki M, Wilson TE, Cui J, Levine BD. Prolonged head-down tilt 2419 
exposure reduces maximal cutaneous vasodilator and sweating capacity in humans. J Appl 2420 
Physiol 94: 2330–2336, 2003. 2421 
13.  Dargahi N, Katsara M, Tselios T, Androutsou M-E, de Courten M, Matsoukas J, 2422 
Apostolopoulos V. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2423 
7, 2017. 2424 
 117 
14.  Davis SL, Wilson TE, Vener JM, Crandall CG, Petajan JH, White AT. Pilocarpine-2425 
induced sweat gland function in individuals with multiple sclerosis. J Appl Physiol 98: 2426 
1740–1744, 2005. 2427 
15.  Filingeri D, Chaseling G, Hoang P, Barnett M, Davis SL, Jay O. Afferent 2428 
thermosensory function in relapsing-remitting multiple sclerosis following exercise-induced 2429 
increases in body temperature. Exp. Physiol. 2017. 2430 
16.  Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, Frohman EM. 2431 
Uhthoff’s phenomena in MS—clinical features and pathophysiology. Nat Rev Neurol 9: 2432 
535–540, 2013. 2433 
17.  Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of 2434 
arterial smooth muscle by acetylcholine. Nature 288: 373–376, 1980. 2435 
18.  Gibbons CH, Illigens BMW, Wang N, Freeman R. Quantification of sweat gland 2436 
innervation: a clinical-pathologic correlation. Neurology 72: 1479–1486, 2009. 2437 
19.  Givon U, Zeilig G, Achiron A. Gait analysis in multiple sclerosis: Characterization of 2438 
temporal–spatial parameters using GAITRite functional ambulation system. Gait Posture 2439 
29: 138–142, 2009. 2440 
20.  Gonzales B, Chopard G, Charry B, Berger E, Tripard J, Magnin E, Groslambert A. 2441 
Effects of a training program involving body cooling on physical and cognitive capacities 2442 
and quality of life in multiple sclerosis patients: A pilot study. Eur Neurol 78: 71–77, 2017. 2443 
21.  de Graaf WL, Zwanenburg JJM, Visser F, Wattjes MP, Pouwels PJW, Geurts JJG, 2444 
Polman CH, Barkhof F, Luijten PR, Castelijns JA. Lesion detection at seven Tesla in 2445 
multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. Eur Radiol 22: 2446 
221–231, 2012. 2447 
22.  Hämäläinen P, Ikonen A, Romberg A, Helenius H, Ruutiainen J. The effects of heat 2448 
stress on cognition in persons with multiple sclerosis. Mult Scler J 18: 489–497, 2012. 2449 
23.  Hjortskov N., Jepsen L. T., Nielsen B., Juul A., Skakkebæk N. E. Pilocarpine 2450 
iontophoresis test: an index of physiological sweat secretion? Clin Physiol 15: 409–414, 2451 
2008. 2452 
24.  Holowatz LA, Thompson CS, Minson CT, Kenney WL. Mechanisms of acetylcholine-2453 
mediated vasodilatation in young and aged human skin. J Physiol 563: 965–973, 2005. 2454 
25.  Holowatz Lacy A., Thompson Caitlin S., Kenney W. Larry. l‐Arginine supplementation 2455 
or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin. J 2456 
Physiol 574: 573–581, 2006. 2457 
26.  Huang M, Allen DR, Keller DM, Fadel PJ, Frohman EM, Davis SL. Impaired carotid 2458 
baroreflex control of arterial blood pressure in multiple sclerosis. J Neurophysiol 116: 81–2459 
87, 2016. 2460 
 118 
27.  Kellogg DL, Crandall CG, Liu Y, Charkoudian N, Johnson JM. Nitric oxide and 2461 
cutaneous active vasodilation during heat stress in humans. J Appl Physiol 85: 824–829, 2462 
1998. 2463 
28.  Kellogg DL, Liu Y, Kosiba IF, O’Donnell D. Role of nitric oxide in the vascular effects 2464 
of local warming of the skin in humans. J Appl Physiol 86: 1185–1190, 1999. 2465 
29.  Kellogg DL, Zhao JL, Coey U, Green JV. Acetylcholine-induced vasodilation is mediated 2466 
by nitric oxide and prostaglandins in human skin. J Appl Physiol 98: 629–632, 2005. 2467 
30.  Khan F, Davidson NC, Littleford RC, Litchfield SJ, Struthers AD, Belch JJ. Cutaneous 2468 
vascular responses to acetylcholine are mediated by a prostanoid-dependent mechanism in 2469 
man. Vasc Med 2: 82–86, 1997. 2470 
31.  Khan F, Newton DJ, Smyth EC, Belch JJF. Influence of vehicle resistance on 2471 
transdermal iontophoretic delivery of acetylcholine and sodium nitroprusside in humans. J 2472 
Appl Physiol 97: 883–887, 2004. 2473 
32.  Kimura K, Low DA, Keller DM, Davis SL, Crandall CG. Cutaneous blood flow and 2474 
sweat rate responses to exogenous administration of acetylcholine and methacholine. J Appl 2475 
Physiol 102: 1856–1861, 2007. 2476 
33.  Krnjajic D, Allen DR, Butts CL, Keller DM. Carotid baroreflex control of heart rate is 2477 
enhanced, while control of mean arterial pressure is preserved during whole-body heat 2478 
stress in young healthy men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311.4: R735-2479 
R741, 2016. 2480 
34.  Mahé G, Abraham P, Humeau-Heurtier A, Gascoin L, Lefthériotis G, Durand S. 2481 
Evidence for a vasomotor cyclo-oxygenase dependent mechanism of sensitization at the 2482 
cutaneous level. Br J Clin Pharmacol 80: 185–192, 2015. 2483 
35.  Mayer RF, Denny-Brown D. Conduction velocity in peripheral nerve during experimental 2484 
demyelination in the cat. Neurology 14: 714–714, 1964. 2485 
36.  McDonald WI, Sears TA. Effect of a demyelinating lesion on conduction in the central 2486 
nervous system studied in single nerve fibres. J Physiol 207: 53P-54P, 1970. 2487 
37.  Moran D, Epstein Y, Keren G, Laor A, Sherez J, Shapiro Y. Calculation of mean 2488 
arterial pressure during exercise as a function of heart rate. Appl Human Sci 14: 293–295, 2489 
1995. 2490 
38.  Narayanan S, Fu L, Pioro E, Stefano ND, Collins DL, Francis GS, Antel JP, Matthews 2491 
PM, Arnold DL. Imaging of axonal damage in multiple sclerosis: Spatial distribution of 2492 
magnetic resonance imaging lesions. Ann Neurol 41: 385–391, 1997. 2493 
39.  Noronha MJ, Vas CJ, Aziz H. Autonomic dysfunction (sweating responses) in multiple 2494 
sclerosis. J Neurol Neurosurg Psychiatry 31: 19–22, 1968. 2495 
 119 
40.  Qiu W, Raven S, Wu J-S, Bundell C, Hollingsworth P, Carroll WM, Mastaglia FL, 2496 
Kermode AG. Hypothalamic lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry 2497 
82: 819, 2011. 2498 
41.  Saari A, Tolonen U, Pääkkö E, Suominen K, Jauhiainen J, Sotaniemi KA, Myllylä VV. 2499 
Sweating impairment in patients with multiple sclerosis. Acta Neurol Scand 120: 358–363, 2500 
2009. 2501 
42.  Saari A, Tolonen U, Pääkkö E, Suominen K, Jauhiainen J, Sotaniemi KA, Myllylä VV. 2502 
Sudomotor dysfunction in patients with optic neuritis. Clin Auton Res 20: 199–204, 2010. 2503 
43.  Sato F, Owen M, Matthes R, Sato K, Gisolfi CV. Functional and morphological changes 2504 
in the eccrine sweat gland with heat acclimation. J Appl Physiol Bethesda Md 1985 69: 2505 
232–236, 1990. 2506 
44.  Sato K, Sato F. Individual variations in structure and function of human eccrine sweat 2507 
gland. Am J Physiol - Regul Integr Comp Physiol 245: R203–R208, 1983. 2508 
45.  Smith K. Conduction properties of central demyelinated and remyelinated axons, and their 2509 
relation to symptom production in demyelinating disorders. 1994. 2510 
46.  Smith KJ. Sodium channels and multiple sclerosis: Roles in symptom production, damage 2511 
and therapy. Brain Pathol 17: 230–242, 2007. 2512 
47.  Tartas M, Durand S, Koïtka A, Bouyé P, Saumet JL, Abraham P. Anodal current 2513 
intensities above 40 microA interfere with current-induced axon-reflex vasodilatation in 2514 
human skin. J Vasc Res 41: 261–267, 2004. 2515 
48.  Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The 2516 
Lancet 0, 2018. 2517 
49.  Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden 2518 
Angenstörungen. Arch Für Psychiatr Nervenkrankh 21: 55–116, 1890. 2519 
50.  Vas CJ. Sexual impotence and some autonomic disturbances in men with multiple 2520 
sclerosis. Acta Neurol Scand 45: 166, 1969. 2521 
 2522 
  2523 
 120 
Table 1.  Subject characteristics 2524 
 CON (n=9) MS (n=9) p-value 
Age (yrs) 31.7 ± 2.0 35.4 ± 2.1 0.31 
Weight (kg) 72.0 ± 3.5 68.4 ± 3.0 0.53 
Height (cm) 169.6 ± 1.8 169.5 ± 2.4 0.97 
BMI (kg/m2) 25.0 ± 1.2 23.7 ± 0.6 0.43 
BSA (m2) 1.8 ± 0.0 1.8 ± 0.0 0.66 
Heart Rate (bpm) 68.4 ± 4.4 63.1 ± 3.2 0.44 
 2525 
BMI, body mass index; BSA, body surface area. 2526 
  2527 
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Figure 1.  Mean change in sweat rate (∆ SR) above baseline transepithelial water loss (±SD) to 2528 
intradermal infusions of increasing log-molar doses of methacholine (MCh) in individuals with 2529 
multiple sclerosis (MS) and healthy controls (CON). 2530 
 2531 
Figure 2.  Mean change in cutaneous vascular conductance(∆ %CVCmax) from baseline (±SD) 2532 
(panel A); and mean group (bars) and individual (small squares) responses in EC50 2533 
concentrations (panel B) to intradermal infusions of increasing log-molar doses of methacholine 2534 
(MCh) in individuals with multiple sclerosis (MS) and healthy controls (CON). 2535 
 2536 
Figure 3.  Mean change in cutaneous vascular conductance(∆ %CVCmax) from baseline (±SD) 2537 
(panel A); and mean group (bars) and individual (small squares) responses in EC50 2538 
concentrations (panel B) to intradermal infusions of increasing log-molar doses of sodium 2539 
nitroprusside (SNP) in individuals with multiple sclerosis (MS) and healthy controls (CON). 2540 
 2541 
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Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system 2559 
that often leads to autonomic dysfunction elsewhere.  As a result of chronic inflammation and 2560 
subsequent demyelination, there is impairment in neural signaling that can lead to an array of 2561 
symptomology.  Unique to MS, individuals suffering from this disease experience a temporary 2562 
worsening of their symptoms when in a hyperthermic state.  This process, known as Uhthoff’s 2563 
phenomenon, can often be a dangerous aspect of the disease that can have a substantial impact 2564 
on the quality of life of those with MS.  Adding to this complexity, there is evidence of 2565 
sudomotor impairments as a result of MS, thus potentially limiting these individual’s capacity for 2566 
heat loss.  Since the body’s primary mechanism of heat loss is the recruitment of- and the 2567 
secretion-from sweat glands, these circumstances suggest individuals with MS may have a 2568 
unique situation in which they are very heat sensitive (Uhthoff’s phenomenon), meanwhile 2569 
unable to adequately prevent becoming hyperthermic (reduced heat loss capacity) in otherwise 2570 
compensable conditions.  2571 
 While the projects performed in this dissertation do not provide a cure for the problems 2572 
associated with heat in the MS population, the results of these studies provide insight into the 2573 
vulnerability of these individuals to battle against rises in body temperature, and thus fend off the 2574 
onset of Uhthoff’s phenomenon.  Using a methodical approach, the projects laid out in this 2575 
dissertation took a unique approach to determine:  2576 
1. Specific Aim 1: Does MS effect the autonomic control of thermoregulatory effecter 2577 
organs during a passive whole-body heat stress? 2578 
2. Specific Aim 2: Does MS effect thermoregulatory responses to exercise of a fixed 2579 
metabolic heat production? 2580 
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3. Specific Aim 3: Does MS effect sweat gland and cutaneous vasculature responses to 2581 
peripheral stimuli independent of changes in core temperature? 2582 
The results of Specific Aim 1 were the first to quantitatively identify that thermoregulatory 2583 
reflex increases in sweating were blunted as a result of a passive heat stress.  Additionally, our 2584 
findings indicate that the control of the cutaneous vasculature is preserved in individuals with 2585 
MS relative to healthy matched control subjects.  These findings support the idea that MS can 2586 
lead to autonomic thermoregulatory impairments, potentially reducing an individual’s capacity 2587 
for heat loss as evidenced by the reduced sweat rates as a function of elevations in core body 2588 
temperature.  Because the primary measures of this study were taken on an exposed forearm not 2589 
under any heat stress conditions, the results of this technique indicate that the thermoregulatory 2590 
abnormalities observed are likely of central origin.   2591 
Findings from Specific Aim 2 provided evidence of reduced whole-body sweat rates as 2592 
exercise duration increased, as well as a reduction in the sensitivity for sweat rate to increase as a 2593 
function of changes in mean body temperature (i.e., thermosensitivity) compared to healthy 2594 
controls.  Additionally, although counter to our hypothesis, there were not statistically significant 2595 
elevations in core body temperature, locally-obtained steady state sweat rate, or measures of skin 2596 
blood flow.  Taken together these results indicate that there are thermoregulatory deficits that 2597 
persist during physical activity as a result of MS, however at light to moderate heat loads, these 2598 
differences may not be of sufficient magnitude to elicit statistically significant rises in core body 2599 
temperature.  That being said, 2 of the 12 MS participants had to terminate exercise due to onset 2600 
of Uhthoff’s phenomenon as a result of exercise-induced increases in core body temperature, 2601 
underlining the importance of understanding the capability for these individuals to dissipate heat.  2602 
These findings suggest that while light exercise in thermoneutral environments may be 2603 
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compensable for individuals with MS, caution should be exercised in this population when 2604 
individuals exercise under more stressful conditions.   2605 
There was no evidence of peripheral thermoregulatory effector-organ function in MS as a 2606 
result of Specific Aim 3.  Using intradermal microdialysis to locally administer thermoregulatory 2607 
agonists to the sweat glands and cutaneous vasculature resulted in similar sweating and skin 2608 
blood flow responses between MS and healthy controls.  These findings confirm the notion from 2609 
Specific Aim 1 that MS effects thermoregulatory function primarily through central- rather than 2610 
peripheral impairments.  Additionally, these findings demonstrate that both endothelial 2611 
dependent as well as endothelial independent vasodilation occurs similarly between MS and 2612 
matched healthy individuals.  Taken together, the results of Specific Aim 3 “rule out” peripheral 2613 
maladaptions, and further support the notion that more research should be focused on the precise 2614 
mechanisms by which sweating is blunted by MS within the central nervous system.  2615 
In conclusion, the findings from these 3 projects provide novel information on the impact of 2616 
MS on thermoregulatory control and function.  As a result of MS, there seems to be a blunted 2617 
neural control and function of thermoregulatory sweating.  These sweating abnormalities are 2618 
apparent during physical activity, however at lower heat loads it seems the blunted sweating 2619 
responses do not significantly contribute to excessive rises in core body temperature.  The results 2620 
of these studies can be utilized by clinicians to create a more informed treatment plan for their 2621 
MS patients.  Additionally, these results can be passed on to future investigators interesting in 2622 
taking steps toward better isolating an exact cause and eventual treatment of Uhthoff’s 2623 
phenomenon in the MS population.  2624 
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